BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. [PMID: 18173375 DOI: 10.1146/annurev.immunol.26.021607.090331] [Cited by in Crossref: 2989] [Cited by in F6Publishing: 2937] [Article Influence: 213.5] [Reference Citation Analysis]
Number Citing Articles
1 Michielin O, Hoeller C. Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treatment Reviews 2015;41:660-70. [DOI: 10.1016/j.ctrv.2015.05.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
2 Wang Y, Chen H, Zhang T, Yang X, Zhong J, Wang Y, Chi Y, Wu M, An T, Li J, Zhao X, Dong Z, Wang Z, Zhao J, Zhuo M, Huang J. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. Ann Transl Med 2021;9:33. [PMID: 33553326 DOI: 10.21037/atm-20-1513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol. 2012;4:pii: a006957. [PMID: 22661634 DOI: 10.1101/cshperspect.a006957] [Cited by in Crossref: 189] [Cited by in F6Publishing: 184] [Article Influence: 18.9] [Reference Citation Analysis]
4 Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L. Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol 2015;42:448-58. [PMID: 25965363 DOI: 10.1053/j.seminoncol.2015.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
5 Lin S, Yeh T, Song J, Hung M, Cheng M, Liao F, Li A, Cheng S, Lin L, Chiu C, Wu M, Lin Y, Hsiao W, Sun M, Wang Y, Huang C, Tang Y, Chang H, Huang Z, Chao Y, Shih C, Pan S, Wu S, Kuo C, Ueng S. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. Bioorganic Chemistry 2018;77:600-7. [DOI: 10.1016/j.bioorg.2018.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis 2018;12:1753465817750075. [PMID: 29385894 DOI: 10.1177/1753465817750075] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
7 Liu T, Song S, Wang X, Hao J. Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. Eur J Med Chem 2021;210:112954. [PMID: 33158576 DOI: 10.1016/j.ejmech.2020.112954] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Liu M, Sun Q, Wei F, Ren X. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biol Med 2020;17:626-39. [PMID: 32944395 DOI: 10.20892/j.issn.2095-3941.2020.0112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013;191:1011-5. [PMID: 23804712 DOI: 10.4049/jimmunol.1300652] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
10 Wang W, Shen G, Wu S, Song S, Ni Y, Suo Z, Meng X, Li D, Zhou L, Hao R, Zhao Y, Bai L, Hou L, Liu B, Liu G. PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget 2017;8:50782-91. [PMID: 28881603 DOI: 10.18632/oncotarget.15006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biol Ther 2015;16:1014-8. [PMID: 26016850 DOI: 10.1080/15384047.2015.1046650] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Pezeshki PS, Rezaei N. Immune checkpoint inhibition in COVID-19: risks and benefits. Expert Opin Biol Ther 2021;:1-7. [PMID: 33543652 DOI: 10.1080/14712598.2021.1887131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Carreras J, Lopez-guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E. High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma. JCO 2009;27:1470-6. [DOI: 10.1200/jco.2008.18.0513] [Cited by in Crossref: 220] [Cited by in F6Publishing: 102] [Article Influence: 16.9] [Reference Citation Analysis]
14 Li K, Cheng X, Tilevik A, Davis SJ, Zhu C. In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. J Biol Chem 2017;292:6799-809. [PMID: 28270509 DOI: 10.1074/jbc.M116.763888] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 da Silva EN, Baker A, Alshekaili J, Karpe K, Cook MC. A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease. PLoS One. 2018;13:e0204477. [PMID: 30303980 DOI: 10.1371/journal.pone.0204477] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 van der Werf N, Redpath SA, Azuma M, Yagita H, Taylor MD. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog 2013;9:e1003215. [PMID: 23516361 DOI: 10.1371/journal.ppat.1003215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
17 Haut LH, Lin SW, Tatsis N, DiMenna LJ, Giles-Davis W, Pinto AR, Ertl HC. Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. Eur J Immunol 2010;40:3426-38. [PMID: 21108465 DOI: 10.1002/eji.201040440] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
18 Wykes MN, Horne-Debets JM, Leow CY, Karunarathne DS. Malaria drives T cells to exhaustion. Front Microbiol 2014;5:249. [PMID: 24904561 DOI: 10.3389/fmicb.2014.00249] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
19 Satou A, Nakamura S. EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency. Cancer Med 2021. [PMID: 34387382 DOI: 10.1002/cam4.4198] [Reference Citation Analysis]
20 Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J, Ferté C. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018;15:748-62. [DOI: 10.1038/s41571-018-0111-2] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 40.0] [Reference Citation Analysis]
21 Kitagawa Y, Akiyoshi T, Yamamoto N, Mukai T, Hiyoshi Y, Yamaguchi T, Nagasaki T, Fukunaga Y, Hirota T, Noda T, Kawachi H. Tumor-infiltrating PD-1+ immune cell density is associated with response to neoadjuvant chemoradiotherapy in rectal cancer. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.01.004] [Reference Citation Analysis]
22 Jung CJ, Yang HJ, Bang SH, Lee WJ, Won CH, Lee MW, Song Y, Chang SE. Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression. J Clin Med 2021;10:5200. [PMID: 34768720 DOI: 10.3390/jcm10215200] [Reference Citation Analysis]
23 Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227-42. [PMID: 23470321 DOI: 10.1038/nri3405] [Cited by in Crossref: 1496] [Cited by in F6Publishing: 1380] [Article Influence: 166.2] [Reference Citation Analysis]
24 Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, Xiao C, Bonorino C, Lu LF, Bui JD, Hui E. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity 2019;51:1059-1073.e9. [PMID: 31757674 DOI: 10.1016/j.immuni.2019.11.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
25 Bhatt S, Shen GQ, Li Y, Qian S, Ragni MV, Lu L. Hepatic stellate cell-conditioned myeloid cells provide a novel therapy for prevention of factor VIII antibody formation in mice. Exp Hematol. 2015;43:277-285. [PMID: 25534204 DOI: 10.1016/j.exphem.2014.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
26 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
27 Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019;38:255. [PMID: 31196207 DOI: 10.1186/s13046-019-1259-z] [Cited by in Crossref: 180] [Cited by in F6Publishing: 174] [Article Influence: 60.0] [Reference Citation Analysis]
28 Hsu PC, Yang CT, Jablons DM, You L. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. Biomedicines 2018;6:E114. [PMID: 30544524 DOI: 10.3390/biomedicines6040114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
29 Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (Basel) 2020;12:E3285. [PMID: 33172030 DOI: 10.3390/cancers12113285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
30 Venigalla RK, Guttikonda PJ, Eckstein V, Ho AD, Sertel S, Lorenz HM, Tretter T. Identification of a human Th1-like IFNγ-secreting Treg subtype deriving from effector T cells. J Autoimmun 2012;39:377-87. [PMID: 22824211 DOI: 10.1016/j.jaut.2012.06.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
31 Kansy B, Lang S. [Immunotherapy - The New Era of Oncology]. Laryngorhinootologie 2018;97:S3-S47. [PMID: 29905353 DOI: 10.1055/s-0043-121594] [Reference Citation Analysis]
32 Pistoia V, Morandi F, Bianchi G, Pezzolo A, Prigione I, Raffaghello L. Immunosuppressive microenvironment in neuroblastoma. Front Oncol 2013;3:167. [PMID: 23805414 DOI: 10.3389/fonc.2013.00167] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
33 Radziewicz H, Ibegbu CC, Hon H, Bédard N, Bruneau J, Workowski KA, Knechtle SJ, Kirk AD, Larsen CP, Shoukry NH. Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. J Immunol. 2010;184:2410-2422. [PMID: 20100932 DOI: 10.4049/jimmunol.0902994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. Oncoimmunology 2013;2:e23403. [PMID: 23802081 DOI: 10.4161/onci.23403] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
35 Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell 2018;33:1017-1032.e7. [PMID: 29894689 DOI: 10.1016/j.ccell.2018.05.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 23.3] [Reference Citation Analysis]
36 Marcucci F, Rumio C, Corti A. Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. Biochim Biophys Acta Rev Cancer 2017;1868:571-83. [PMID: 29056539 DOI: 10.1016/j.bbcan.2017.10.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
37 Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer 2020;126:2193-205. [PMID: 32125707 DOI: 10.1002/cncr.32796] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
38 Shigemori T, Toiyama Y, Okugawa Y, Yamamoto A, Yin C, Narumi A, Ichikawa T, Ide S, Shimura T, Fujikawa H, Yasuda H, Hiro J, Yoshiyama S, Ohi M, Araki T, Kusunoki M. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. Ann Surg Oncol 2019;26:876-83. [PMID: 30565045 DOI: 10.1245/s10434-018-07112-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
39 Borrie AE, Maleki Vareki S. T Lymphocyte–Based Cancer Immunotherapeutics. Biology of T Cells - Part A. Elsevier; 2018. pp. 201-76. [DOI: 10.1016/bs.ircmb.2018.05.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
40 Wu H, Miao M, Zhang G, Hu Y, Ming Z, Zhang X. Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. Immunol Invest. 2009;38:408-421. [PMID: 19811417 DOI: 10.1080/08820130902912332] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
41 Xu S, Yang Q, Bai J, Tao T, Tang L, Chen Y, Chung CS, Fallon EA, Ayala A. Blockade of endothelial, but not epithelial, cell expression of PD-L1 following severe shock attenuates the development of indirect acute lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2020;318:L801-12. [PMID: 31994912 DOI: 10.1152/ajplung.00108.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ. Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. Pharmacogenomics J 2017;17:528-34. [PMID: 27241062 DOI: 10.1038/tpj.2016.46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Wu L, Lv C, Su Y, Li C, Zhang H, Zhao X, Li M. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol 2019;35:251-6. [PMID: 30325236 DOI: 10.1080/09513590.2018.1519787] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
44 Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy 2016;8:1233-44. [DOI: 10.2217/imt-2016-0048] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
45 Arrieta O, Montes-Servín E, Hernandez-Martinez JM, Cardona AF, Casas-Ruiz E, Crispín JC, Motola D, Flores-Estrada D, Barrera L. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget 2017;8:101994-2005. [PMID: 29254220 DOI: 10.18632/oncotarget.22025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
46 Zhang D, Huang J, Zhang C, Guan Y, Guo Q. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:369-79. [PMID: 31196371 DOI: 10.3779/j.issn.1009-3419.2019.06.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Abbas AK, Lichtman AH, Pillai S, Baker DL. IMMUNOLOGICAL TOLERANCE. Cellular and Molecular Immunology. Elsevier; 2010. pp. 243-63. [DOI: 10.1016/b978-1-4160-3123-9.50018-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The pathogenesis of sepsis. Annu Rev Pathol. 2011;6:19-48. [PMID: 20887193 DOI: 10.1146/annurev-pathol-011110-130327] [Cited by in Crossref: 337] [Cited by in F6Publishing: 335] [Article Influence: 30.6] [Reference Citation Analysis]
49 Lamichhane P, Amin NP, Agarwal M, Lamichhane N. Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? Medicines (Basel) 2018;5:E114. [PMID: 30360504 DOI: 10.3390/medicines5040114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
50 Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci. 2012;69:1997-2008. [PMID: 22205213 DOI: 10.1007/s00018-011-0907-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
51 Cao Q, Zheng C, Xie Z, Liu L, Zhu J, Jin T. The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3. Journal of Neuroimmunology 2020;338:577079. [DOI: 10.1016/j.jneuroim.2019.577079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
52 Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Immunological effects of hypomethylating agents. Expert Rev Hematol 2017;10:745-52. [PMID: 28644756 DOI: 10.1080/17474086.2017.1346470] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
53 Kalim M, Iqbal Khan MS, Zhan J. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des 2020;95:552-66. [PMID: 32166894 DOI: 10.1111/cbdd.13677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y, Chan G, Huang Z, Hu B, Li H, Jablons DM, You L. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget 2017;8:114576-87. [PMID: 29383103 DOI: 10.18632/oncotarget.23051] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
55 Zhao X, He L, Mao K, Chen D, Jiang H, Liu Z. The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study. Medicine (Baltimore) 2018;97:e0276. [PMID: 29642147 DOI: 10.1097/MD.0000000000010276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS. Anti-PD-L1 peptide improves survival in sepsis. J Surg Res 2017;208:33-9. [PMID: 27993215 DOI: 10.1016/j.jss.2016.08.099] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
57 Li J, Van Valkenburgh J, Hong X, Conti PS, Zhang X, Chen K. Small molecules as theranostic agents in cancer immunology. Theranostics 2019;9:7849-71. [PMID: 31695804 DOI: 10.7150/thno.37218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
58 Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett 2019;17:2960-8. [PMID: 30854074 DOI: 10.3892/ol.2019.9910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
59 Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy 2015;7:777-92. [PMID: 26250412 DOI: 10.2217/imt.15.49] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
60 Boer K, de Wit LE, Peters FS, Hesselink DA, Hofland LJ, Betjes MG, Looman CW, Baan CC. Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. Clin Epigenetics 2016;8:116. [PMID: 27891189 DOI: 10.1186/s13148-016-0288-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
61 Ruedas-Torres I, Rodríguez-Gómez IM, Sánchez-Carvajal JM, Guil-Luna S, Larenas-Muñoz F, Pallarés FJ, Carrasco L, Gómez-Laguna J. Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion. Front Immunol 2021;12:671743. [PMID: 34046040 DOI: 10.3389/fimmu.2021.671743] [Reference Citation Analysis]
62 Zhang N, Dou Y, Liu L, Zhang X, Liu X, Zeng Q, Liu Y, Yin M, Liu X, Deng H, Song D. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine 2019;40:151-62. [PMID: 30711516 DOI: 10.1016/j.ebiom.2019.01.054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
63 Kurino T, Matsuda R, Terui A, Suzuki H, Kokubo T, Uehara T, Arano Y, Hisaka A, Hatakeyama H. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. J Immunother Cancer 2020;8:e000400. [PMID: 32041818 DOI: 10.1136/jitc-2019-000400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212-1218. [PMID: 24240160 DOI: 10.1038/ni.2762] [Cited by in Crossref: 532] [Cited by in F6Publishing: 487] [Article Influence: 66.5] [Reference Citation Analysis]
65 Duong SL, Prüss H. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics 2022. [PMID: 35043373 DOI: 10.1007/s13311-022-01184-0] [Reference Citation Analysis]
66 Borkner L, Kaiser A, van de Kasteele W, Andreesen R, Mackensen A, Haanen JB, Schumacher TN, Blank C. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother 2010;59:1173-83. [PMID: 20349059 DOI: 10.1007/s00262-010-0842-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
67 Jain A, Shannon VR, Sheshadri A. Immune-Related Adverse Events: Pneumonitis. Adv Exp Med Biol 2018;995:131-49. [PMID: 30539509 DOI: 10.1007/978-3-030-02505-2_6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
68 Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, O'Mara L, Yang S, Konieczny BT, Sharpe AH, Freeman GJ, Rudensky AY, Ahmed R. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014;211:1905-1918. [PMID: 25113973 DOI: 10.1084/jem.20132577] [Cited by in Crossref: 134] [Cited by in F6Publishing: 131] [Article Influence: 16.8] [Reference Citation Analysis]
69 Idso JM, Lao S, Schloemer NJ, Knipstein J, Burns R, Thakar MS, Malarkannan S. Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway. Oncotarget 2020;11:1799-815. [PMID: 32499867 DOI: 10.18632/oncotarget.27546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
70 Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, Bloem A, Boon L, Flinsenberg T, Compeer E, van den Broek T, Facy O, Ortega-Deballon P, Berthier S, Leguy-Seguin V, Martin L, Ciudad M, Samson M, Trad M, Lorcerie B, Janikashvili N, Saas P, Bonnotte B, Radstake TR. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood 2014;124:2858-66. [PMID: 25232056 DOI: 10.1182/blood-2014-03-563445] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
71 Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer 2017;41:407-12. [PMID: 29096940 DOI: 10.1016/j.currproblcancer.2017.10.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
72 Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecol Oncol 2018;151:381-9. [PMID: 30217369 DOI: 10.1016/j.ygyno.2018.09.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
73 Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 2016;5:e1204507. [PMID: 27757299 DOI: 10.1080/2162402X.2016.1204507] [Cited by in Crossref: 74] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
74 Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, García-Acevez SJ. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther 2020;5:99. [PMID: 32555170 DOI: 10.1038/s41392-020-0205-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
75 Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT. PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Biomark Med 2019;13:1539-41. [PMID: 31631684 DOI: 10.2217/bmm-2019-0344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
76 Juchem KW, Sacirbegovic F, Zhang C, Sharpe AH, Russell K, McNiff JM, Demetris AJ, Shlomchik MJ, Shlomchik WD. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. J Immunol 2018;200:834-46. [PMID: 29212909 DOI: 10.4049/jimmunol.1701076] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
77 Boyer M, Tsao M, Jänne P, Ramalingam S, Pitman Lowenthal S, Alam M. Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape: Nonsmall cell lung cancer landscape. Asia-Pac J Clin Oncol 2014;10:2-10. [DOI: 10.1111/ajco.12189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
78 Raud B, McGuire PJ, Jones RG, Sparwasser T, Berod L. Fatty acid metabolism in CD8+ T cell memory: Challenging current concepts. Immunol Rev 2018;283:213-31. [PMID: 29664569 DOI: 10.1111/imr.12655] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
79 Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS One 2017;12:e0174916. [PMID: 28445479 DOI: 10.1371/journal.pone.0174916] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
80 Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol 2021;6:eabf4034. [PMID: 34739340 DOI: 10.1126/sciimmunol.abf4034] [Reference Citation Analysis]
81 Lamichhane NS, An J, Liu Q, Zhang W. Primary malignant mucosal melanoma of the upper lip: a case report and review of the literature. BMC Res Notes. 2015;8:499. [PMID: 26420268 DOI: 10.1186/s13104-015-1459-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
82 Hughes MJ, McGettrick HM, Sapey E. Importance of validating antibody panels: Anti-PD-L1 clone binds AF700 fluorophore. J Immunol Methods 2020;483:112795. [PMID: 32464141 DOI: 10.1016/j.jim.2020.112795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 2011;9:1013-33. [PMID: 22029521 DOI: 10.1586/eri.11.122] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
84 Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer 2015;16:e25-35. [DOI: 10.1016/j.cllc.2015.02.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 72] [Article Influence: 8.7] [Reference Citation Analysis]
85 Ryu H, Shin D, Lee DH, Won H, Kwon SH. A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status. Carcinogenesis 2018;39:72-83. [DOI: 10.1093/carcin/bgx121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
86 Kleeman SO, Leedham SJ. Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. Cancers (Basel) 2020;12:E3355. [PMID: 33202731 DOI: 10.3390/cancers12113355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015;12:201-8. [PMID: 26487965 DOI: 10.7497/j.issn.2095-3941.2015.0046] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
88 Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 2012;9:81-90. [PMID: 22198819 DOI: 10.1007/s11904-011-0106-4] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 7.9] [Reference Citation Analysis]
89 Chang W, Kim J, Kim Y, Kim Y, Lee J, Azuma M, Yagita H, Kang C. Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy. J Immunol 2008;181:6707-10. [DOI: 10.4049/jimmunol.181.10.6707] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 7.6] [Reference Citation Analysis]
90 Tavares ABM, Albuquerque EL. Vibration properties of immune‐oncological drugs. J Raman Spectroscopy. [DOI: 10.1002/jrs.6297] [Reference Citation Analysis]
91 Wang J, Wang M, Li Z, Wu X, Zhang X, Julius A, Zhong H, Huang X, Chen M, Tan H, Yi H. Impact of PD-1 gene polymorphism and its interaction with tea drinking on susceptibility to tuberculosis. Epidemiol Infect 2021;149:e29. [PMID: 33436123 DOI: 10.1017/S0950268821000042] [Reference Citation Analysis]
92 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
93 Sakai S, Kawamura I, Okazaki T, Tsuchiya K, Uchiyama R, Mitsuyama M. PD-1-PD-L1 pathway impairs Th1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guerin. International Immunology 2010;22:915-25. [DOI: 10.1093/intimm/dxq446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
94 Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012;23 Suppl 8:viii35-40. [PMID: 22918926 DOI: 10.1093/annonc/mds261] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
95 Baas M, Besançon A, Goncalves T, Valette F, Yagita H, Sawitzki B, Volk HD, Waeckel-Enée E, Rocha B, Chatenoud L, You S. TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 2016;5:e08133. [PMID: 26824266 DOI: 10.7554/eLife.08133] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
96 Chen L, Wang L, Li X, Zhang G, Li Z, Wang Y. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer. DNA Cell Biol 2021;40:405-13. [PMID: 33605797 DOI: 10.1089/dna.2020.6232] [Reference Citation Analysis]
97 Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv 2017;1:2643-54. [PMID: 29296917 DOI: 10.1182/bloodadvances.2017012534] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 11.4] [Reference Citation Analysis]
98 Plege A, Borns K, Baars W, Schwinzer R. Suppression of Human T-Cell Activation and Expansion of Regulatory T Cells by Pig Cells Overexpressing PD-Ligands. Transplantation 2009;87:975-82. [DOI: 10.1097/tp.0b013e31819c85e8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
99 He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015;5:13110. [PMID: 26279307 DOI: 10.1038/srep13110] [Cited by in Crossref: 198] [Cited by in F6Publishing: 204] [Article Influence: 28.3] [Reference Citation Analysis]
100 Baues C, Semrau R, Gaipl US, Bröckelmann PJ, Rosenbrock J, Engert A, Marnitz S. Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group. Strahlenther Onkol 2017;193:95-9. [PMID: 27704149 DOI: 10.1007/s00066-016-1050-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
101 Wu B, Fu X, Huang B, Tong X, Zheng H, Huang S, Lu F. Comparison of dynamic expressions of Tim-3 and PD-1 in the brains between toxoplasmic encephalitis-resistant BALB/c and -susceptible C57BL/6 mice. Parasitol Res 2014;113:1261-7. [PMID: 24481903 DOI: 10.1007/s00436-014-3764-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
102 Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Mol Cancer 2021;20:76. [PMID: 34001144 DOI: 10.1186/s12943-021-01363-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Qi X, Jia B, Zhao X, Yu D. Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. Onco Targets Ther 2017;10:5745-54. [PMID: 29238207 DOI: 10.2147/OTT.S148182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
104 Evangelidou M, Tseveleki V, Vamvakas SS, Probert L. TNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responses. Immunol Cell Biol 2010;88:586-95. [PMID: 20212506 DOI: 10.1038/icb.2010.12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
105 Sanaei MJ, Pourbagheri-Sigaroodi A, Kaveh V, Abolghasemi H, Ghaffari SH, Momeny M, Bashash D. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. Eur J Pharmacol 2021;909:174404. [PMID: 34363829 DOI: 10.1016/j.ejphar.2021.174404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Hille-rehfeld A. Der Warburg-Effekt im Duell von Tumorzellen und Immunsystem. Chemie in unserer Zeit 2016;50:305-9. [DOI: 10.1002/ciuz.201600749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Tai H, Xing H, Xiang D, Zhu Z, Mei H, Sun W, Zhang W. Monocyte Programmed Death Ligand-1, A Predicator for 28-Day Mortality in Septic Patients. Am J Med Sci 2018;355:362-7. [PMID: 29661350 DOI: 10.1016/j.amjms.2017.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
108 McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702. [PMID: 22888354 DOI: 10.1155/2012/513702] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
109 Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS 2018;126:732-8. [PMID: 30160018 DOI: 10.1111/apm.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
110 Quesnel B. Tumor dormancy and immunoescape. APMIS 2008;116:685-94. [PMID: 18834412 DOI: 10.1111/j.1600-0463.2008.01163.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
111 Patel A, Bisno DI, Patel HV, Ghodoussipour S, Saraiya B, Mayer T, Singer EA. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma. J Cancer Immunol (Wilmington) 2021;3:115-36. [PMID: 34263255 DOI: 10.33696/cancerimmunol.3.047] [Reference Citation Analysis]
112 Krittikarux S, Wudhikarn K, Tangnuntachai N, Assanasen T, Sukswai N, Asawapanumas T, Chanswangphuwana C. The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma. Leuk Lymphoma 2020;61:3395-403. [PMID: 32820659 DOI: 10.1080/10428194.2020.1808209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
113 Jiang Z, Pan Z, Ren X. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:138-42. [PMID: 28228226 DOI: 10.3779/j.issn.1009-3419.2017.02.09] [Reference Citation Analysis]
114 Teruya K, Kusumoto Y, Eto H, Nakamichi N, Shirahata S. Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract. Mar Drugs 2019;17:E421. [PMID: 31331053 DOI: 10.3390/md17070421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
115 Torrez M, Braunberger RC, Yilmaz E, Agarwal S. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature. Pathol Res Pract 2020;216:153146. [PMID: 32853962 DOI: 10.1016/j.prp.2020.153146] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Zhang JQ, Plitas G. Immunotherapeutic strategies in breast cancer: A clinical update. J Surg Oncol 2021;123:710-7. [PMID: 33155281 DOI: 10.1002/jso.26287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y. Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance. Front Immunol. 2019;10:93. [PMID: 30774630 DOI: 10.3389/fimmu.2019.00093] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
118 Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol 2018;71:189-94. [PMID: 29097600 DOI: 10.1136/jclinpath-2017-204853] [Cited by in Crossref: 94] [Cited by in F6Publishing: 104] [Article Influence: 18.8] [Reference Citation Analysis]
119 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
120 Yu Z, Guo J, Liu Y, Wang M, Liu Z, Gao Y, Huang L. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J Nanobiotechnology 2022;20:9. [PMID: 34983554 DOI: 10.1186/s12951-021-01205-8] [Reference Citation Analysis]
121 Merindol N, Champagne MA, Duval M, Soudeyns H. CD8+ T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood 2011;118:4480-8. [DOI: 10.1182/blood-2011-04-349241] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
122 Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol 2018;25:1814-27. [PMID: 29500764 DOI: 10.1245/s10434-018-6379-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
123 Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807-21. [PMID: 32612154 DOI: 10.1038/s41423-020-0488-6] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 33.0] [Reference Citation Analysis]
124 Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J. Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. PLoS One 2016;11:e0152448. [PMID: 27031235 DOI: 10.1371/journal.pone.0152448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
125 Gay F, D'agostino M, Giaccone L, Genuardi M, Festuccia M, Boccadoro M, Bruno B. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. Clinical Lymphoma Myeloma and Leukemia 2017;17:471-8. [DOI: 10.1016/j.clml.2017.06.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
126 Ramonell KM, Zhang W, Hadley A, Chen CW, Fay KT, Lyons JD, Klingensmith NJ, McConnell KW, Coopersmith CM, Ford ML. CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis. PLoS One 2017;12:e0188882. [PMID: 29232699 DOI: 10.1371/journal.pone.0188882] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
127 Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011;187:1113-9. [PMID: 21697455 DOI: 10.4049/jimmunol.1100056] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 7.6] [Reference Citation Analysis]
128 Hu S, Liu X, Li T, Li Z, Hu F. LAG3 (CD223) and autoimmunity: Emerging evidence. J Autoimmun 2020;112:102504. [PMID: 32576412 DOI: 10.1016/j.jaut.2020.102504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol. 2013;369:243-262. [PMID: 23463204 DOI: 10.1007/978-3-642-27340-7_10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
130 Wehrhan F, Weber M, Baran C, Agaimy A, Büttner-Herold M, Kesting M, Ries J. PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood. J Craniomaxillofac Surg 2021;49:118-25. [PMID: 33358116 DOI: 10.1016/j.jcms.2020.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreño LJ, Venkataswamy MM, Kim J, Lazar-Molnar E, Lauvau G, Chang YT, Liu Z, Bittman R, Al-Shamkhani A, Cox LR, Jervis PJ, Veerapen N, Besra GS, Porcelli SA. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014;40:105-16. [PMID: 24412610 DOI: 10.1016/j.immuni.2013.12.004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 8.8] [Reference Citation Analysis]
132 Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015;290:8110-8120. [PMID: 25645920 DOI: 10.1074/jbc.m114.612689] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
133 Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. Cancers (Basel) 2018;10:E171. [PMID: 29857493 DOI: 10.3390/cancers10060171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
134 Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. Front Immunol 2018;9:3062. [PMID: 30740109 DOI: 10.3389/fimmu.2018.03062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
135 Giesbrecht K, Förmer S, Sähr A, Heeg K, Hildebrand D. Streptococcal Pyrogenic Exotoxin A-Stimulated Monocytes Mediate Regulatory T-Cell Accumulation through PD-L1 and Kynurenine. Int J Mol Sci 2019;20:E3933. [PMID: 31412561 DOI: 10.3390/ijms20163933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
136 Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J, Lin J, Chen L, Zeng D. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol 2015;194:560-74. [PMID: 25488990 DOI: 10.4049/jimmunol.1402157] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
137 Zhang F, Gong W. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis. Int Immunopharmacol 2020;83:106481. [PMID: 32339986 DOI: 10.1016/j.intimp.2020.106481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2016;127:869-81. [PMID: 26702065 DOI: 10.1182/blood-2015-10-673236] [Cited by in Crossref: 264] [Cited by in F6Publishing: 251] [Article Influence: 37.7] [Reference Citation Analysis]
139 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
140 Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med 2019;8:E1534. [PMID: 31557787 DOI: 10.3390/jcm8101534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
141 Takehara T, Wakamatsu E, Machiyama H, Nishi W, Emoto K, Azuma M, Soejima K, Fukunaga K, Yokosuka T. PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment. Commun Biol 2021;4:581. [PMID: 33990697 DOI: 10.1038/s42003-021-02111-3] [Reference Citation Analysis]
142 Liu MY, Klement JD, Langan CJ, van Riggelen J, Liu K. Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells. Cell Immunol 2021;366:104397. [PMID: 34157461 DOI: 10.1016/j.cellimm.2021.104397] [Reference Citation Analysis]
143 Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Netherby-Winslow CS, Ayers KN, Lukacher AE. Balancing Inflammation and Central Nervous System Homeostasis: T Cell Receptor Signaling in Antiviral Brain TRM Formation and Function. Front Immunol 2020;11:624144. [PMID: 33584727 DOI: 10.3389/fimmu.2020.624144] [Reference Citation Analysis]
145 Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Annals of Surgery 2019;269:471-8. [DOI: 10.1097/sla.0000000000002616] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 18.7] [Reference Citation Analysis]
146 Zhang K, Desai A, Zeng D, Gong T, Lu P, Wang M. Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting. Oncotarget 2017;8:10748-59. [PMID: 27863374 DOI: 10.18632/oncotarget.13314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
147 Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;. [PMID: 31294749 DOI: 10.1001/jamaoncol.2019.1478] [Cited by in Crossref: 213] [Cited by in F6Publishing: 223] [Article Influence: 71.0] [Reference Citation Analysis]
148 Castellanos EH, Feld E, Estrada MV, Sanders ME, Massion PP, Johnson DB, Balko JM, Horn L. Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. JCO Precis Oncol 2017;1:PO. [PMID: 32913978 DOI: 10.1200/PO.17.00049] [Reference Citation Analysis]
149 Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016;7:59976-86. [PMID: 27527850 DOI: 10.18632/oncotarget.11045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
150 Kapelios CJ, Nanas JN, Malliaras K. Allogeneic cardiosphere-derived cells for myocardial regeneration: current progress and recent results. Future Cardiology 2016;12:87-100. [DOI: 10.2217/fca.15.72] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
151 Kwiecień I, Rutkowska E, Polubiec-Kownacka M, Raniszewska A, Rzepecki P, Domagała-Kulawik J. Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. Transl Lung Cancer Res 2021;10:1679-89. [PMID: 34012784 DOI: 10.21037/tlcr-20-1103] [Reference Citation Analysis]
152 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
153 Rosignoli G, Lim CH, Bower M, Gotch F, Imami N. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol 2009;157:90-7. [PMID: 19659774 DOI: 10.1111/j.1365-2249.2009.03960.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
154 Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights from infections. J Immunol 2012;188:2957-65. [PMID: 22442493 DOI: 10.4049/jimmunol.1100038] [Cited by in Crossref: 102] [Cited by in F6Publishing: 108] [Article Influence: 10.2] [Reference Citation Analysis]
155 Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity 2018;49:264-274.e4. [PMID: 30076099 DOI: 10.1016/j.immuni.2018.06.012] [Cited by in Crossref: 149] [Cited by in F6Publishing: 153] [Article Influence: 37.3] [Reference Citation Analysis]
156 Gu Z, Da Silva CG, Van der Maaden K, Ossendorp F, Cruz LJ. Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics 2020;12:E1054. [PMID: 33158166 DOI: 10.3390/pharmaceutics12111054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
157 Wu H, Lo Y, Chan A, Law KS, Mok MY. Rel B-modified dendritic cells possess tolerogenic phenotype and functions on lupus splenic lymphocytes in vitro. Immunology 2016;149:48-61. [PMID: 27278094 DOI: 10.1111/imm.12628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
158 Chun C, Smith AST, Kim H, Kamenz DS, Lee JH, Lee JB, Mack DL, Bothwell M, Clelland CD, Kim DH. Astrocyte-derived extracellular vesicles enhance the survival and electrophysiological function of human cortical neurons in vitro. Biomaterials 2021;271:120700. [PMID: 33631652 DOI: 10.1016/j.biomaterials.2021.120700] [Reference Citation Analysis]
159 Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom 2017;92:100-14. [PMID: 28054442 DOI: 10.1002/cyto.b.21508] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
160 Huang G, Wen Q, Zhao Y, Gao Q, Bai Y. NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS One 2013;8:e61602. [PMID: 23585913 DOI: 10.1371/journal.pone.0061602] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
161 Podar K, Pecherstorfer M. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother 2017;18:1061-79. [PMID: 28604120 DOI: 10.1080/14656566.2017.1340942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
162 Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015;125:3393-400. [PMID: 25833961 DOI: 10.1182/blood-2015-02-567453] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 22.4] [Reference Citation Analysis]
163 Kim JE, Lim M. The role of checkpoints in the treatment of GBM. J Neurooncol 2015;123:413-23. [PMID: 25749875 DOI: 10.1007/s11060-015-1747-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
164 Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit Rev Oncol Hematol. 2016;97:65-71. [PMID: 26321371 DOI: 10.1016/j.critrevonc.2015.08.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
165 Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 2016;6:30093. [PMID: 27456063 DOI: 10.1038/srep30093] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 21.5] [Reference Citation Analysis]
166 Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Zhu L. Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies. CPT Pharmacometrics Syst Pharmacol 2019;8:962-70. [PMID: 31710163 DOI: 10.1002/psp4.12476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
167 Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov 2021. [PMID: 33686237 DOI: 10.1038/s41573-021-00155-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
168 Khan MA, Khan A. Role of NKT Cells during Viral Infection and the Development of NKT Cell-Based Nanovaccines. Vaccines (Basel) 2021;9:949. [PMID: 34579186 DOI: 10.3390/vaccines9090949] [Reference Citation Analysis]
169 Yao A, Liu F, Chen K, Tang L, Liu L, Zhang K, Yu C, Bian G, Guo H, Zheng J, Cheng P, Ju G, Wang J. Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice. Neurotherapeutics 2014;11:636-50. [PMID: 24853068 DOI: 10.1007/s13311-013-0254-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
170 Nagamatsu T, Barrier BF, Schust DJ. The regulation of T‐cell cytokine production by ICOS–B7H2 interactions at the human fetomaternal interface. Immunol Cell Biol 2011;89:417-25. [DOI: 10.1038/icb.2010.101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
171 Sacdalan DB, Lucero JA. The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. Onco Targets Ther 2021;14:2053-64. [PMID: 33776452 DOI: 10.2147/OTT.S278089] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020;9:S28-42. [PMID: 32055496 DOI: 10.21037/gs.2019.10.18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
173 Ostrand-Rosenberg S. Myeloid derived-suppressor cells: their role in cancer and obesity. Curr Opin Immunol 2018;51:68-75. [PMID: 29544121 DOI: 10.1016/j.coi.2018.03.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 13.0] [Reference Citation Analysis]
174 Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 2013;123:1044-56. [PMID: 23391724 DOI: 10.1172/JCI65325] [Cited by in Crossref: 76] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
175 Liang SK, Chien LH, Chang GC, Tsai YH, Su WC, Chen YM, Huang MS, Lin HC, Fang WT, Hung HH, Jiang SS, Chen CY, Chen KY, Chang IS, Hsiung CA, Chen CJ, Yang PC; GELAC Study Group. Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. Front Oncol 2021;11:753788. [PMID: 34631591 DOI: 10.3389/fonc.2021.753788] [Reference Citation Analysis]
176 Butte MJ, Peña-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 2008;45:3567-72. [PMID: 18585785 DOI: 10.1016/j.molimm.2008.05.014] [Cited by in Crossref: 156] [Cited by in F6Publishing: 155] [Article Influence: 11.1] [Reference Citation Analysis]
177 Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity. Bioessays. 2013;35:623-631. [PMID: 23666891 DOI: 10.1002/bies.201300004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
178 Lin N, Song Y, Zhu J. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Chin J Cancer Res 2020;32:303-18. [PMID: 32694896 DOI: 10.21147/j.issn.1000-9604.2020.03.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
179 Shao L, Peng Q, Du K, He J, Dong Y, Lin X, Li J, Wu J. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag Res 2017;9:249-58. [PMID: 28721097 DOI: 10.2147/CMAR.S139889] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
180 Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-383. [PMID: 18799145 DOI: 10.1016/j.immuni.2008.08.004] [Cited by in Crossref: 360] [Cited by in F6Publishing: 338] [Article Influence: 25.7] [Reference Citation Analysis]
181 Wang Y, Tan J, Hu P, Pei Q, Wen Y, Ma W, Shi K, Li Z, Li H, Cheng F, Gu X, Yao X, Man Y, Zhao R, Feng S, Ding X, Yang T. Traditional Chinese medicine compound, Bu Sheng Hui Yang Fang, promotes the proliferation of lymphocytes in the immunosuppressed mice potentially by upregulating IL-4 signaling. Biomed Pharmacother 2021;134:111107. [PMID: 33341059 DOI: 10.1016/j.biopha.2020.111107] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Hirth M, Gandla J, Kuner R. A checkpoint to pain. Nat Neurosci 2017;20:897-9. [PMID: 28653690 DOI: 10.1038/nn.4586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
183 Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D, Ugolini S, Vély F, Vivier E. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 2013;122:394-404. [PMID: 23687088 DOI: 10.1182/blood-2013-01-481705] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 9.9] [Reference Citation Analysis]
184 Lee LF, Logronio K, Tu GH, Zhai W, Ni I, Mei L, Dilley J, Yu J, Rajpal A, Brown C, Appah C, Chin SM, Han B, Affolter T, Lin JC. Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A 2012;109:12674-9. [PMID: 22733769 DOI: 10.1073/pnas.1203795109] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 8.5] [Reference Citation Analysis]
185 Ida S, Takahashi H, Kawabata-Iwakawa R, Mito I, Tada H, Chikamatsu K. Tissue-resident memory T cells correlate with the inflammatory tumor microenvironment and improved prognosis in head and neck squamous cell carcinoma. Oral Oncol 2021;122:105508. [PMID: 34507204 DOI: 10.1016/j.oraloncology.2021.105508] [Reference Citation Analysis]
186 Kim YJ, Park SJ, Broxmeyer HE. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. J Immunol 2011;187:2291-301. [PMID: 21795591 DOI: 10.4049/jimmunol.1002650] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
187 Robak P, Smolewski P, Robak T. Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opin Emerg Drugs 2015;20:423-47. [PMID: 26153226 DOI: 10.1517/14728214.2015.1046432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Annals of Oncology 2012;23:viii28-34. [DOI: 10.1093/annonc/mds260] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
189 Gupta K, Uchel T, Karamian G, Loschner A. Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer. Cancer Treat Res Commun 2021;28:100439. [PMID: 34333246 DOI: 10.1016/j.ctarc.2021.100439] [Reference Citation Analysis]
190 Kagabu M, Nagasawa T, Sato C, Fukagawa Y, Kawamura H, Tomabechi H, Takemoto S, Shoji T, Baba T. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. Int J Mol Sci 2020;21:E2335. [PMID: 32230938 DOI: 10.3390/ijms21072335] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
191 Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, Madan RA, Gulley JL, Schlom J. Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. J Circ Biomark 2016;5:5. [PMID: 28936253 DOI: 10.5772/62322] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
192 Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, Rosenquist R, Hansson L, Österborg A, Mellstedt H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017;102:562-72. [PMID: 27927767 DOI: 10.3324/haematol.2016.151100] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 11.5] [Reference Citation Analysis]
193 Mekki A, Dercle L, Lichtenstein P, Nasser G, Marabelle A, Champiat S, Chouzenoux E, Balleyguier C, Ammari S. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer 2019;119:44-56. [PMID: 31415986 DOI: 10.1016/j.ejca.2019.06.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
194 Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol 2021;12:731798. [PMID: 34539412 DOI: 10.3389/fphar.2021.731798] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Ji S, Lee J, Lee ES, Kim DH, Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17:1910-22. [PMID: 33522416 DOI: 10.1080/21645515.2020.1866951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
196 Liu X, Zhan Y, Xu W, Liu X, Geng Y, Liu L, Da J, Wang J, Zhang X, Jin H, Liu Z, Guo S, Zhang B, Li Y. Prognostic and immunological role of Fam20C in pan-cancer. Biosci Rep 2021;41:BSR20201920. [PMID: 33306121 DOI: 10.1042/BSR20201920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
197 Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol. 2013;107:517-522. [PMID: 23129549 DOI: 10.1002/jso.23281] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
198 Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Huang J, Abot E, Limbach K, Chuang I, Tamminga C, Epstein JE, Villasante E. Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. Hum Vaccin Immunother 2015;11:2705-15. [PMID: 26292027 DOI: 10.1080/21645515.2015.1019186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
199 Aldarouish M, Wang C. Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res 2016;35:157. [PMID: 27686848 DOI: 10.1186/s13046-016-0439-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
200 Upadhya A, Yadav KS, Misra A. Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opin Drug Deliv 2021;18:73-102. [PMID: 32954834 DOI: 10.1080/17425247.2021.1825377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 de Kleijn S, Langereis JD, Leentjens J, Kox M, Netea MG, Koenderman L, Ferwerda G, Pickkers P, Hermans PW. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One 2013;8:e72249. [PMID: 24015224 DOI: 10.1371/journal.pone.0072249] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 10.9] [Reference Citation Analysis]
202 Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021;13:334. [PMID: 33477569 DOI: 10.3390/cancers13020334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
203 Chen Q, Deng T, Han D. Testicular immunoregulation and spermatogenesis. Seminars in Cell & Developmental Biology 2016;59:157-65. [DOI: 10.1016/j.semcdb.2016.01.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
204 Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity. 2019;52:144-160. [PMID: 31298041 DOI: 10.1080/08916934.2019.1641200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
205 Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci 2018;43:1014-32. [PMID: 30287140 DOI: 10.1016/j.tibs.2018.09.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
206 Miller ML, Sun Y, Fu YX. Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. J Immunol 2009;183:32-6. [PMID: 19535622 DOI: 10.4049/jimmunol.0900690] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
207 Freeman GJ. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl Acad Sci U S A 2008;105:10275-6. [PMID: 18650389 DOI: 10.1073/pnas.0805459105] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
208 Singh AK, Gaur P, Das SN. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions. Hum Immunol. 2014;75:250-260. [PMID: 24373798 DOI: 10.1016/j.humimm.2013.12.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
209 Stühler V, Maas JM, Rausch S, Stenzl A, Bedke J. Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opin Biol Ther 2020;20:83-94. [PMID: 31587590 DOI: 10.1080/14712598.2020.1677601] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
210 Kursunel MA, Esendagli G. The untold story of IFN-γ in cancer biology. Cytokine & Growth Factor Reviews 2016;31:73-81. [DOI: 10.1016/j.cytogfr.2016.07.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 7.5] [Reference Citation Analysis]
211 Camelliti S, Le Noci V, Bianchi F, Moscheni C, Arnaboldi F, Gagliano N, Balsari A, Garassino MC, Tagliabue E, Sfondrini L, Sommariva M. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. J Exp Clin Cancer Res 2020;39:236. [PMID: 33168050 DOI: 10.1186/s13046-020-01721-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
212 Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, Liu Q, Callahan MV, Sluder AE, Gelfand JA, Chen H, Poznansky MC. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J 2019;33:6596-608. [PMID: 30802149 DOI: 10.1096/fj.201802067RR] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 16.7] [Reference Citation Analysis]
213 Zhou B, Jiang Q, Xiao X, Xu X, Xu Y, Kong Y, Zhang W, Zeng Y, Liu X, Luo B. Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells. Nanoscale 2019;11:7996-8011. [PMID: 30969294 DOI: 10.1039/c9nr01434a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
214 Thangavelu G, Smolarchuk C, Anderson CC. Co-inhibitory molecules: Controlling the effectors or controlling the controllers? Self Nonself 2010;1:77-88. [PMID: 21487510 DOI: 10.4161/self.1.2.11548] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
215 Thude H, Schipler AD, Treszl A, Peine S, Koch M, Sterneck M, Nashan B. Lack of association between CTLA-4 and PDCD1 polymorphisms and acute rejection in German liver transplant recipients. Human Immunology 2013;74:1041-5. [DOI: 10.1016/j.humimm.2013.04.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
216 Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, Simmons P, Cherryholmes G, Carnahan J, William J, Spaulding B, Satnick IR, Inzunza HD, Taylor C, Cogswell J, Novotny J, Oroudjev E, Winther H. Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. Appl Immunohistochem Mol Morphol 2018;26:6-12. [PMID: 29189265 DOI: 10.1097/PAI.0000000000000605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
217 Ye L, Ma S, Robinson BW, Creaney J. Immunotherapy strategies for mesothelioma - the role of tumor specific neoantigens in a new era of precision medicine. Expert Rev Respir Med 2019;13:181-92. [PMID: 30596292 DOI: 10.1080/17476348.2019.1563488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
218 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. [PMID: 27574444 DOI: 10.2147/ott.s105862] [Cited by in Crossref: 297] [Cited by in F6Publishing: 192] [Article Influence: 49.5] [Reference Citation Analysis]
219 Allen PB, Gordon LI. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. Expert Rev Hematol 2016;9:939-49. [PMID: 27622603 DOI: 10.1080/17474086.2016.1235970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
220 Ebisutani N, Tozawa K, Matsuda I, Nakamura K, Tamura A, Hara K, Kondo T, Terada T, Tomita T, Oshima T, Fukui H, Hirota S, Miwa H. A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis. Dig Dis Sci 2021;66:2461-5. [PMID: 32780186 DOI: 10.1007/s10620-020-06529-3] [Reference Citation Analysis]
221 Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012;209:1201-17. [PMID: 22641383 DOI: 10.1084/jem.20112741] [Cited by in Crossref: 516] [Cited by in F6Publishing: 492] [Article Influence: 51.6] [Reference Citation Analysis]
222 Hamashima R, Uchino J, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Association of immune checkpoint inhibitors with respiratory infections: A review. Cancer Treat Rev 2020;90:102109. [PMID: 33038863 DOI: 10.1016/j.ctrv.2020.102109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Gülave B, Hew MN, de Groot JS, Rodwell L, Teerenstra S, Fabriek BO. High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors. ESMO Open 2021;6:100107. [PMID: 33887689 DOI: 10.1016/j.esmoop.2021.100107] [Reference Citation Analysis]
224 Xiong W, Gao Y, Wei W, Zhang J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer 2021;7:837-46. [PMID: 33903073 DOI: 10.1016/j.trecan.2021.03.003] [Reference Citation Analysis]
225 Zhang S, Wang L, Li M, Zhang F, Zeng X. The PD-1/PD-L pathway in rheumatic diseases. J Formos Med Assoc 2021;120:48-59. [PMID: 32334916 DOI: 10.1016/j.jfma.2020.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Jayaraj P, Sen S. Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. Indian J Ophthalmol 2019;67:1983-7. [PMID: 31755433 DOI: 10.4103/ijo.IJO_2056_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
227 Huang Z, Su W, Lu T, Wang Y, Dong Y, Qin Y, Liu D, Sun L, Jiao W. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. Front Pharmacol 2020;11:578091. [PMID: 33117170 DOI: 10.3389/fphar.2020.578091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
228 Chen Y, Wu S, Guo G, Fei L, Guo S, Yang C, Fu X, Wu Y. Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog. 2011;7:e1001347. [PMID: 21750671 DOI: 10.1371/journal.ppat.1001347] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
229 Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, Sathe M, Grein J, Blumenschein W, Pinheiro EM, Chackerian A. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest 2018;128:644-54. [PMID: 29337311 DOI: 10.1172/JCI94586] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 12.8] [Reference Citation Analysis]
230 Li P, Yang L, Li T, Bin S, Sun B, Huang Y, Yang K, Shan D, Gu H, Li H. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice. Front Oncol 2020;10:1143. [PMID: 32766150 DOI: 10.3389/fonc.2020.01143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation 2013;10:111. [PMID: 24015822 DOI: 10.1186/1742-2094-10-111] [Cited by in F6Publishing: 40] [Reference Citation Analysis]
232 Pike R, Thomas N, Workman S, Ambrose L, Guzman D, Sivakumaran S, Johnson M, Thorburn D, Harber M, Chain B, Stauss HJ. PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients. Front Immunol 2016;7:126. [PMID: 27148254 DOI: 10.3389/fimmu.2016.00126] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
233 Tsirigotis P, Shimoni A, Nagler A. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. Ann Med 2014;46:384-96. [PMID: 24888385 DOI: 10.3109/07853890.2014.918463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
234 Ibañez-Vega J, Vilchez C, Jimenez K, Guevara C, Burgos PI, Naves R. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. J Autoimmun 2021;123:102702. [PMID: 34311143 DOI: 10.1016/j.jaut.2021.102702] [Reference Citation Analysis]
235 Frebel H, Oxenius A. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Trends Immunol 2013;34:193-9. [PMID: 23333205 DOI: 10.1016/j.it.2012.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
236 Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, Piechnik A, Bojarska-Junak A, Dmoszynska A, Giannopoulos K. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 2012;7:e35178. [PMID: 22532845 DOI: 10.1371/journal.pone.0035178] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
237 Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Ann Transl Med 2020;8:1095. [PMID: 33145314 DOI: 10.21037/atm-20-3735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
238 Arruda LCM, de Azevedo JTC, de Oliveira GLV, Scortegagna GT, Rodrigues ES, Palma PVB, Brum DG, Guerreiro CT, Marques VD, Barreira AA, Covas DT, Simões BP, Voltarelli JC, Oliveira MC, Malmegrim KCR. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. Clin Immunol 2016;169:47-57. [PMID: 27318116 DOI: 10.1016/j.clim.2016.06.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
239 Koopmans I, Hendriks D, Samplonius DF, van Ginkel RJ, Heskamp S, Wierstra PJ, Bremer E, Helfrich W. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology 2018;7:e1466016. [PMID: 30221065 DOI: 10.1080/2162402X.2018.1466016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
240 Nahas MR, Soiffer RJ, Kim HT, Alyea EP, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, Mcmasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood 2018;131:2836-45. [DOI: 10.1182/blood-2017-05-780239] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
241 Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Viganò M. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol. 2012;56:1239-1246. [PMID: 22326467 DOI: 10.1016/j.jhep.2011.12.032] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
242 Menon S, Shin S, Dy G. Advances in Cancer Immunotherapy in Solid Tumors. Cancers (Basel) 2016;8:E106. [PMID: 27886124 DOI: 10.3390/cancers8120106] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 14.7] [Reference Citation Analysis]
243 Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-h1 expressed by activated CD8 T cells is essential for their survival. J Immunol. 2011;187:5606-5614. [PMID: 22025548 DOI: 10.4049/jimmunol.1003976] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
244 Tong H, Hao Y, Wang K, Xiang L, Lu T. The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review. Medicine (Baltimore) 2020;99:e19367. [PMID: 32176058 DOI: 10.1097/MD.0000000000019367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
245 Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2018;9:10284-93. [PMID: 29535806 DOI: 10.18632/oncotarget.22888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
246 Scriven JE, Tenforde MW, Levitz SM, Jarvis JN. Modulating host immune responses to fight invasive fungal infections. Curr Opin Microbiol 2017;40:95-103. [PMID: 29154044 DOI: 10.1016/j.mib.2017.10.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
247 Jiang W, Pan S, Chen X, Wang ZW, Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer 2021;20:116. [PMID: 34496886 DOI: 10.1186/s12943-021-01406-7] [Reference Citation Analysis]
248 Liang S, Yang J, Lin Y, Li T, Zhao W, Zhao J, Dong C. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. Front Immunol 2021;12:682262. [PMID: 34305915 DOI: 10.3389/fimmu.2021.682262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Lu Y, Wang G, Li C. Expression of peripheral monocytic programmed death ligand-1 in severe sepsis combined with HBV-related cirrhosis. A pilot observational study. Cent Eur J Immunol 2021;46:217-24. [PMID: 34764790 DOI: 10.5114/ceji.2021.108179] [Reference Citation Analysis]
250 Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. [PMID: 28389661 DOI: 10.1038/s41598-017-00462-8] [Cited by in Crossref: 296] [Cited by in F6Publishing: 288] [Article Influence: 59.2] [Reference Citation Analysis]
251 Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008;14:550-9. [PMID: 18986838 DOI: 10.1016/j.molmed.2008.09.010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
252 Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J 2019;9:22. [PMID: 30783096 DOI: 10.1038/s41408-019-0185-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
253 Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 2018;131:1809-19. [PMID: 29449276 DOI: 10.1182/blood-2017-07-796342] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 31.3] [Reference Citation Analysis]
254 Asmar R, Yang J, Carvajal RD. Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016;12:313-25. [PMID: 27013881 DOI: 10.2147/TCRM.S78039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
255 Ou JN, Wiedeman AE, Stevens AM. TNF-α and TGF-β counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. Sci Rep 2012;2:295. [PMID: 22389764 DOI: 10.1038/srep00295] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
256 Ferla V, Rossi FG, Goldaniga MC, Baldini L. Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. Front Oncol 2020;10:506. [PMID: 32457824 DOI: 10.3389/fonc.2020.00506] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
257 Pan T, Liu Z, Yin J, Zhou T, Liu J, Qu H. Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression. Mediators Inflamm 2015;2015:539841. [PMID: 26063974 DOI: 10.1155/2015/539841] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
258 Chatzidionysiou K, Liapi M, Tsakonas G, Gunnarsson I, Catrina A. Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift? Clin Rheumatol 2021;40:1687-95. [PMID: 32989505 DOI: 10.1007/s10067-020-05420-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Yan J, Zhang Y, Zhang JP, Liang J, Li L, Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLoS One. 2013;8:e58006. [PMID: 23526963 DOI: 10.1371/journal.pone.0058006] [Cited by in Crossref: 86] [Cited by in F6Publishing: 97] [Article Influence: 9.6] [Reference Citation Analysis]
260 Zhang Y, Mou GZ, Li TZ, Xu WT, Zhang T, Xue H, Zuo WB, Li YN, Luo YH, Jin CH. PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research. Technol Cancer Res Treat 2021;20:15330338211004942. [PMID: 33759637 DOI: 10.1177/15330338211004942] [Reference Citation Analysis]
261 Li Q, Quan L, Lyu J, He Z, Wang X, Meng J, Zhao Z, Zhu L, Liu X, Li H. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget 2016;7:64967-76. [PMID: 27533458 DOI: 10.18632/oncotarget.11274] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
262 Klepsch V, Hermann-Kleiter N, Baier G. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunol Lett 2016;178:31-6. [PMID: 26992368 DOI: 10.1016/j.imlet.2016.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
263 Kamphorst AO, Araki K, Ahmed R. Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine 2015;33 Suppl 2:B21-8. [PMID: 26022562 DOI: 10.1016/j.vaccine.2014.12.082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
264 Low JL, Huang Y, Sooi K, Ang Y, Chan ZY, Spencer K, Jeyasekharan AD, Sundar R, Goh BC, Soo R, Yong WP. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. Int J Cancer 2021;149:169-76. [PMID: 33634869 DOI: 10.1002/ijc.33534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Melero I, Martinez-Forero I, Dubrot J, Suarez N, Palazón A, Chen L. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin Cancer Res 2009;15:1507-9. [PMID: 19240168 DOI: 10.1158/1078-0432.CCR-08-2931] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
266 Kalinin RS, Ukrainskaya VM, Chumakov SP, Moysenovich AM, Tereshchuk VM, Volkov DV, Pershin DS, Maksimov EG, Zhang H, Maschan MA, Rubtsov YP, Stepanov AV. Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival. Front Mol Biosci 2021;8:745286. [PMID: 34722633 DOI: 10.3389/fmolb.2021.745286] [Reference Citation Analysis]
267 Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol 2021;22:104. [PMID: 33849634 DOI: 10.1186/s13059-021-02331-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open 2019;9:e027066. [PMID: 31796469 DOI: 10.1136/bmjopen-2018-027066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
269 Ding L, Dong HY, Zhou TR, Wang YH, Yan T, Li JC, Wang ZY, Li J, Liang C. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Cancer Med 2021. [PMID: 34382349 DOI: 10.1002/cam4.4190] [Reference Citation Analysis]
270 Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009;229:5-11. [PMID: 19426211 DOI: 10.1111/j.1600-065X.2009.00784.x] [Cited by in Crossref: 207] [Cited by in F6Publishing: 141] [Article Influence: 15.9] [Reference Citation Analysis]
271 Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 2017;9:493-511. [PMID: 28717401 DOI: 10.1177/1758834017711380] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
272 Ferrari SM, Fallahi P, La Motta C, Elia G, Ragusa F, Ruffilli I, Patrizio A, Baldini E, Ulisse S, Antonelli A. Recent advances in precision medicine for the treatment of anaplastic thyroid cancer. Expert Review of Precision Medicine and Drug Development 2018;4:37-49. [DOI: 10.1080/23808993.2019.1565940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
273 Zhou Y, Huang T, Zhang J, Cheng ASL, Yu J, Kang W, To KF. Emerging roles of Hippo signaling in inflammation and YAP-driven tumor immunity. Cancer Lett 2018;426:73-9. [PMID: 29654891 DOI: 10.1016/j.canlet.2018.04.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
274 Pretto F, Neri D. Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure. Pharmacol Ther 2013;139:405-11. [PMID: 23711792 DOI: 10.1016/j.pharmthera.2013.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
275 Chin YT, Wei PL, Ho Y, Nana AW, Changou CA, Chen YR, Yang YS, Hsieh MT, Hercbergs A, Davis PJ, Shih YJ, Lin HY. Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocr Relat Cancer 2018;25:533-45. [PMID: 29555649 DOI: 10.1530/ERC-17-0376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
276 Benlahrech A, Yasmin A, Westrop SJ, Coleman A, Herasimtschuk A, Page E, Kelleher P, Gotch F, Imami N, Patterson S. Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy. Clin Exp Immunol 2012;170:212-21. [PMID: 23039892 DOI: 10.1111/j.1365-2249.2012.04647.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
277 Connell BJ, Chang SY, Prakash E, Yousfi R, Mohan V, Posch W, Wilflingseder D, Moog C, Kodama EN, Clayette P, Lortat-Jacob H. A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation. PLoS One 2016;11:e0165386. [PMID: 27788205 DOI: 10.1371/journal.pone.0165386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
278 Francis DM, Thomas SN. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv Drug Deliv Rev 2017;114:33-42. [PMID: 28455187 DOI: 10.1016/j.addr.2017.04.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
279 Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, Janin A, Zhao WL. Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther 2020;5:15. [PMID: 32296035 DOI: 10.1038/s41392-020-0113-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
280 Gomez GVB, Rinck-Junior JA, Oliveira C, Silva DHL, Mamoni RL, Lourenço GJ, Moraes AM, Lima CSP. PDCD1 gene polymorphisms as regulators of T-lymphocyte activity in cutaneous melanoma risk and prognosis. Pigment Cell Melanoma Res 2018;31:308-17. [PMID: 29090522 DOI: 10.1111/pcmr.12665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
281 Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290:72-79. [PMID: 24908630 DOI: 10.1016/j.cellimm.2014.05.006] [Cited by in Crossref: 187] [Cited by in F6Publishing: 177] [Article Influence: 23.4] [Reference Citation Analysis]
282 Bayraktar R, Van Roosbroeck K. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev 2018;37:33-44. [PMID: 29282605 DOI: 10.1007/s10555-017-9724-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 21.0] [Reference Citation Analysis]
283 Kaufmann SH. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol. 2012;33:373-379. [PMID: 22560865 DOI: 10.1016/j.it.2012.03.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
284 Bedke T, Pretsch L, Karakhanova S, Enk AH, Mahnke K. Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10. J Immunol 2010;184:5562-70. [PMID: 20382886 DOI: 10.4049/jimmunol.0902458] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
285 Penaranda C, Kuswanto W, Hofmann J, Kenefeck R, Narendran P, Walker LS, Bluestone JA, Abbas AK, Dooms H. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A 2012;109:12668-73. [PMID: 22733744 DOI: 10.1073/pnas.1203692109] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
286 Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 2018;16:86. [PMID: 29615076 DOI: 10.1186/s12967-018-1460-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
287 Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012;209:201-9. [PMID: 22330682 DOI: 10.1084/jem.20112275] [Cited by in Crossref: 93] [Cited by in F6Publishing: 94] [Article Influence: 9.3] [Reference Citation Analysis]
288 Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014;10:3111-3116. [PMID: 25625924 DOI: 10.4161/21645515.2014.983409] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
289 Gottschalk C, Damuzzo V, Gotot J, Kroczek RA, Yagita H, Murphy KM, Knolle PA, Ludwig-Portugall I, Kurts C. Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. J Am Soc Nephrol 2013;24:543-9. [PMID: 23411785 DOI: 10.1681/ASN.2012101022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
290 Weber MM, Fottner C. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncol Res Treat 2018;41:306-12. [DOI: 10.1159/000488996] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
291 Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, Zhong X, Li X, Qian H, Wang X. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One. 2017;12:e0182692. [PMID: 28796808 DOI: 10.1371/journal.pone.0182692] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 17.2] [Reference Citation Analysis]
292 Draghi A, Chamberlain CA, Furness A, Donia M. Acquired resistance to cancer immunotherapy. Semin Immunopathol 2019;41:31-40. [PMID: 29968044 DOI: 10.1007/s00281-018-0692-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
293 Ye P, Chi X, Cha JH, Luo S, Yang G, Yan X, Yang WH. Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges. Cells 2021;10:3309. [PMID: 34943817 DOI: 10.3390/cells10123309] [Reference Citation Analysis]
294 Attili I, Passaro A, Pavan A, Conte P, De Marinis F, Bonanno L. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? Crit Rev Oncol Hematol 2017;119:30-9. [PMID: 29065983 DOI: 10.1016/j.critrevonc.2017.09.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
295 Cui X, Song P, Zhang L. [New Advances in the Treatment for Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2019;22:355-62. [PMID: 31196369 DOI: 10.3779/j.issn.1009-3419.2019.06.05] [Reference Citation Analysis]
296 Yang Y, Fang T, Cao YL, Lv YX, Chang QQ, Zhang DD. Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis. Evid Based Complement Alternat Med 2020;2020:3587095. [PMID: 32922506 DOI: 10.1155/2020/3587095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
297 Voskamp MJ, Li S, van Daalen KR, Crnko S, Ten Broeke T, Bovenschen N. Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. Cancers (Basel) 2021;13:5387. [PMID: 34771550 DOI: 10.3390/cancers13215387] [Reference Citation Analysis]
298 Marofi F, Rahman HS, Achmad MH, Sergeevna KN, Suksatan W, Abdelbasset WK, Mikhailova MV, Shomali N, Yazdanifar M, Hassanzadeh A, Ahmadi M, Motavalli R, Pathak Y, Izadi S, Jarahian M. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Front Immunol 2021;12:681984. [PMID: 34248965 DOI: 10.3389/fimmu.2021.681984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Frossi B, D'Incà F, Crivellato E, Sibilano R, Gri G, Mongillo M, Danelli L, Maggi L, Pucillo CE. Single-cell dynamics of mast cell-CD4+ CD25+ regulatory T cell interactions. Eur J Immunol 2011;41:1872-82. [PMID: 21509780 DOI: 10.1002/eji.201041300] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
300 Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. J Med Chem 2021. [PMID: 34323489 DOI: 10.1021/acs.jmedchem.1c00876] [Reference Citation Analysis]
301 Hams E, McCarron MJ, Amu S, Yagita H, Azuma M, Chen L, Fallon PG. Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. J Immunol. 2011;186:5648-5655. [PMID: 21490158 DOI: 10.4049/jimmunol.1003161] [Cited by in Crossref: 97] [Cited by in F6Publishing: 104] [Article Influence: 8.8] [Reference Citation Analysis]
302 Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ 2020;27:3209-25. [PMID: 33037393 DOI: 10.1038/s41418-020-00633-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 21.5] [Reference Citation Analysis]
303 Awadasseid A, Yin Q, Wu Y, Zhang W. Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection. Biomed Pharmacother 2021;142:111957. [PMID: 34339917 DOI: 10.1016/j.biopha.2021.111957] [Reference Citation Analysis]
304 Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019;14:793-801. [PMID: 30711649 DOI: 10.1016/j.jtho.2019.01.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
305 Jia L, Liu K, Fei T, Liu Q, Zhao X, Hou L, Zhang W. Programmed cell death-1/programmed cell death-ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages. Exp Ther Med 2021;21:400. [PMID: 33680122 DOI: 10.3892/etm.2021.9831] [Reference Citation Analysis]
306 Canavan M, Floudas A, Veale DJ, Fearon U. The PD-1:PD-L1 axis in Inflammatory Arthritis. BMC Rheumatol 2021;5:1. [PMID: 33423684 DOI: 10.1186/s41927-020-00171-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
307 Jo Y, Ali LA, Shim JA, Lee BH, Hong C. Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield. Cancers (Basel) 2020;12:E2087. [PMID: 32731404 DOI: 10.3390/cancers12082087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, Blanco E, Vera R, Kochan G, Escors D. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front Pharmacol 2020;11:441. [PMID: 32317979 DOI: 10.3389/fphar.2020.00441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
309 Meggyes M, Nagy DU, Szereday L. Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women. J Clin Med 2020;9:E2536. [PMID: 32781525 DOI: 10.3390/jcm9082536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Murakami S, Shibaki R, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thorac Cancer 2020;11:3585-95. [PMID: 33108686 DOI: 10.1111/1759-7714.13721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
311 Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AMM, Soria J, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13:473-86. [DOI: 10.1038/nrclinonc.2016.58] [Cited by in Crossref: 491] [Cited by in F6Publishing: 450] [Article Influence: 81.8] [Reference Citation Analysis]
312 Tang J, Zhou C, Zhang ZJ, Zheng SS. Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis. Hepatobiliary Pancreat Dis Int. 2012;11:125-131. [PMID: 22484578 DOI: 10.1016/s1499-3872(12)60136-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
313 Paulsen EE, Kilvaer TK, Khanehkenari MR, Al-Saad S, Hald SM, Andersen S, Richardsen E, Ness N, Busund LT, Bremnes RM, Donnem T. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. Clin Lung Cancer 2017;18:220-233.e8. [PMID: 27816392 DOI: 10.1016/j.cllc.2016.09.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
314 Atallah-Yunes SA, Kadado AJ, Soe MH. Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review. Curr Probl Cancer 2019;43:504-10. [PMID: 30685067 DOI: 10.1016/j.currproblcancer.2019.01.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
315 Bein J, Thurner L, Hansmann ML, Hartmann S. Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse. Am J Hematol 2020;95:1495-502. [PMID: 32815561 DOI: 10.1002/ajh.25972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
316 Liu T, Lu X, Zhao C, Fu X, Zhao T, Xu W. PD-1 deficiency enhances humoral immunity of malaria infection treatment vaccine. Infect Immun 2015;83:2011-7. [PMID: 25733520 DOI: 10.1128/IAI.02621-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
317 Liu H, Hu M, Deng J, Zhao Y, Peng D, Feng Y, Wang L, Chen Y, Qiu L. A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors. Mol Pharm 2022;19:138-47. [PMID: 34910492 DOI: 10.1021/acs.molpharmaceut.1c00694] [Reference Citation Analysis]
318 Lewis DB, Wilson CB. Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. Infectious Diseases of the Fetus and Newborn. Elsevier; 2011. pp. 80-191. [DOI: 10.1016/b978-1-4160-6400-8.00004-3] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
319 Qiu Z, Du Y. Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis. J Gastrointest Oncol 2021;12:112-20. [PMID: 33708429 DOI: 10.21037/jgo-20-568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Pittet CL, Newcombe J, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation 2011;8:155. [PMID: 22067141 DOI: 10.1186/1742-2094-8-155] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
321 Diesendruck Y, Benhar I. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 2017;30:39-47. [DOI: 10.1016/j.drup.2017.02.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
322 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
323 Mi Y, Han J, Zhu J, Jin T. Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Mol Neurobiol 2021. [PMID: 34480337 DOI: 10.1007/s12035-021-02495-7] [Reference Citation Analysis]
324 Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, Grønbæk K. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015;6:9612-26. [PMID: 25823822 DOI: 10.18632/oncotarget.3324] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 18.2] [Reference Citation Analysis]
325 Matar CG, Anthony NR, O'Flaherty BM, Jacobs NT, Priyamvada L, Engwerda CR, Speck SH, Lamb TJ. Gammaherpesvirus Co-infection with Malaria Suppresses Anti-parasitic Humoral Immunity. PLoS Pathog 2015;11:e1004858. [PMID: 25996913 DOI: 10.1371/journal.ppat.1004858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
326 Chauhan NK, Vajpayee M, Mojumdar K, Singh R, Singh A. Study of CD4+CD8+ Double positive T-lymphocyte phenotype and function in Indian patients infected with HIV-1. J Med Virol 2012;84:845-56. [DOI: 10.1002/jmv.23289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
327 Zou Y, Zhang Z, Liu Y, Liu D, Xu W. Are programmed cell death 1 gene polymorphisms correlated with susceptibility to rheumatoid arthritis?: A meta-analysis. Medicine (Baltimore) 2017;96:e7805. [PMID: 28858091 DOI: 10.1097/MD.0000000000007805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
328 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
329 Clambey ET, Davenport B, Kappler JW, Marrack P, Homann D. Molecules in medicine mini review: the αβ T cell receptor. J Mol Med (Berl) 2014;92:735-41. [PMID: 24848996 DOI: 10.1007/s00109-014-1145-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
330 Zhang YH, Tian M, Tang MX, Liu ZZ, Liao AH. Recent Insight into the Role of the PD-1/PD-L1 Pathway in Feto-Maternal Tolerance and Pregnancy. Am J Reprod Immunol. 2015;74:201-208. [PMID: 25640631 DOI: 10.1111/aji.12365] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
331 Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 2017;8:14754. [PMID: 28345650 DOI: 10.1038/ncomms14754] [Cited by in Crossref: 136] [Cited by in F6Publishing: 144] [Article Influence: 27.2] [Reference Citation Analysis]
332 Matsuyama-Kato A, Murata S, Isezaki M, Takasaki S, Kano R, Konnai S, Ohashi K. Expression analysis of programmed death ligand 2 in tumors caused by the avian oncovirus Marek's disease virus. Arch Virol 2014;159:2123-6. [PMID: 24623086 DOI: 10.1007/s00705-014-2021-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
333 Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 2014;20:256-61. [PMID: 25098285 DOI: 10.1097/PPO.0000000000000061] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 11.1] [Reference Citation Analysis]
334 Toki MI, Syrigos N, Syrigos K. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. Int J Cancer 2021;149:277-86. [PMID: 33300601 DOI: 10.1002/ijc.33429] [Reference Citation Analysis]
335 Neumann K, Ostmann A, Breda PC, Ochel A, Tacke F, Paust HJ, Panzer U, Tiegs G. The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Sci Rep 2019;9:2038. [PMID: 30765734 DOI: 10.1038/s41598-018-38432-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
336 Broxmeyer HE, Farag SS, Rocha V. Cord Blood Hematopoietic Cell Transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. Chichester: John Wiley & Sons, Ltd; 2015. pp. 437-55. [DOI: 10.1002/9781118416426.ch39] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Wang G, Li Z, Tian H, Wu W, Liu C. Modification of sPD1 with CRT induces potent anti-tumor immune responses in vitro and in vivo. Biomed Pharmacother 2015;76:57-64. [PMID: 26653551 DOI: 10.1016/j.biopha.2015.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
338 Albertini MR, Ranheim EA, Zuleger CL, Sondel PM, Hank JA, Bridges A, Newton MA, McFarland T, Collins J, Clements E, Henry MB, Neuman HB, Weber S, Whalen G, Galili U. Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother 2016;65:897-907. [PMID: 27207605 DOI: 10.1007/s00262-016-1846-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
339 Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483-1492. [PMID: 28967485 DOI: 10.1016/s1470-2045(17)30616-2] [Cited by in Crossref: 550] [Cited by in F6Publishing: 267] [Article Influence: 110.0] [Reference Citation Analysis]
340 Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther 2015;4:91-100. [PMID: 27471715 DOI: 10.2147/ITT.S61292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
341 Srinivasan A, Nanton M, Griffin A, McSorley SJ. Culling of activated CD4 T cells during typhoid is driven by Salmonella virulence genes. J Immunol 2009;182:7838-45. [PMID: 19494308 DOI: 10.4049/jimmunol.0900382] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
342 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
343 Dong X, Lu N, Tong Z, Shi Y. Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation. Onco Targets Ther 2021;14:929-36. [PMID: 33603397 DOI: 10.2147/OTT.S267022] [Reference Citation Analysis]
344 Liu M, Miao T, Zhu H, Symonds AL, Li L, Schurich A, Maini MK, Zhang J, Kennedy PT, Li S, Wang P. IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients. J Immunol 2012;188:1534-43. [PMID: 22210908 DOI: 10.4049/jimmunol.1102709] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
345 Kravchenko J, Corsini E, Williams MA, Decker W, Manjili MH, Otsuki T, Singh N, Al-Mulla F, Al-Temaimi R, Amedei A, Colacci AM, Vaccari M, Mondello C, Scovassi AI, Raju J, Hamid RA, Memeo L, Forte S, Roy R, Woodrick J, Salem HK, Ryan EP, Brown DG, Bisson WH, Lowe L, Lyerly HK. Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis 2015;36 Suppl 1:S111-27. [PMID: 26002081 DOI: 10.1093/carcin/bgv033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
346 Ishii H, Afify SM, Hassan G, Salomon DS, Seno M. Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy. Cancers (Basel) 2021;13:2491. [PMID: 34065315 DOI: 10.3390/cancers13102491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
347 Thangavelu G, Murphy KM, Yagita H, Boon L, Anderson CC. The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. Immunobiology 2011;216:918-24. [PMID: 21281982 DOI: 10.1016/j.imbio.2011.01.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
348 Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma. Lancet Oncol. 2015;16:e234-e245. [PMID: 25943068 DOI: 10.1016/s1470-2045(15)70103-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 5.1] [Reference Citation Analysis]
349 Messerschmidt JL, Bhattacharya P, Messerschmidt GL. Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. Curr Oncol Rep 2017;19. [DOI: 10.1007/s11912-017-0625-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
350 Webb GJ, Adams DH. Modeling idiosyncrasy: a novel animal model of drug-induced liver injury. Hepatology. 2015;61:1124-1126. [PMID: 25418789 DOI: 10.1002/hep.27617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
351 Kopalli SR, Kang T, Lee K, Koppula S. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. PRA 2019;14:100-12. [DOI: 10.2174/1574892813666181029142812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
352 Liu C, Jiang J, Gao L, Hu X, Wang F, Shen Y, Yu G, Zhao Z, Zhang X. A Promoter Region Polymorphism in PDCD-1 Gene Is Associated with Risk of Rheumatoid Arthritis in the Han Chinese Population of Southeastern China. Int J Genomics. 2014;2014:247637. [PMID: 24804191 DOI: 10.1155/2014/247637] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
353 Tie Y, Ma X, Zhu C, Mao Y, Shen K, Wei X, Chen Y, Zheng H. Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. Int J Cancer 2017;140:948-58. [PMID: 27813059 DOI: 10.1002/ijc.30501] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
354 Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247-1253. [PMID: 27485741 DOI: 10.1080/17425255.2016.1216976] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
355 Clemens L, Dushek O, Allard J. Intrinsic Disorder in the T Cell Receptor Creates Cooperativity and Controls ZAP70 Binding. Biophys J 2021;120:379-92. [PMID: 33285117 DOI: 10.1016/j.bpj.2020.11.2266] [Reference Citation Analysis]
356 Xu J, Sun HH, Fletcher CD, Hornick JL, Morgan EA, Freeman GJ, Hodi FS, Pinkus GS, Rodig SJ. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. American Journal of Surgical Pathology 2016;40:443-53. [DOI: 10.1097/pas.0000000000000590] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
357 Cremolini C, Vitale E, Rastaldo R, Giachino C. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials (Basel) 2021;11:661. [PMID: 33800368 DOI: 10.3390/nano11030661] [Reference Citation Analysis]
358 Bénigni P, Guénolé M, Bonsang B, Marcorelles P, Schick U, Uguen A. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2020;28:17-22. [DOI: 10.1097/pai.0000000000000792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Lin Z, Chen X, Li Z, Luo Y, Fang Z, Xu B, Han M. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160485. [PMID: 27483468 DOI: 10.1371/journal.pone.0160485] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
360 Bruns M, Wanger J, Utermöhlen O, Deppert W. An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses. Oncotarget 2015;6:38487-503. [PMID: 26513294 DOI: 10.18632/oncotarget.5750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
361 Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 2015;27:384-91. [PMID: 26248256 DOI: 10.1097/CCO.0000000000000212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
362 Zhou L, Zhang Y, Xu H, Hu L, Zhang C, Sun L, Xie Y, Lu H, Zhang Z, Hu W, Lin X. Decreased programmed death-1 expression on the T cells of patients with ankylosing spondylitis. Am J Med Sci 2015;349:488-92. [PMID: 25881983 DOI: 10.1097/MAJ.0000000000000468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
363 Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2015;21:451-67. [PMID: 24917416 DOI: 10.1177/1078155214538087] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
364 Blum S, Martins F, Lübbert M. Immunotherapy in adult acute leukemia. Leuk Res 2017;60:63-73. [PMID: 28756350 DOI: 10.1016/j.leukres.2017.06.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
365 Jiang H, Ni H, Zhang P, Guo X, Wu M, Shen H, Wang J, Wu W, Wu Z, Ding J, Tang R, Zhou S, Chen B, Yu M, Jing H, Liu J. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. Oncoimmunology 2021;10:1943180. [PMID: 34239776 DOI: 10.1080/2162402X.2021.1943180] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
366 Mandleywala K, Shmuel S, Pereira PMR, Lewis JS. Antibody-Targeted Imaging of Gastric Cancer. Molecules 2020;25:E4621. [PMID: 33050602 DOI: 10.3390/molecules25204621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
367 Osawa Y, Kojika E, Nishikawa K, Kimura M, Osakaya S, Miyauchi H, Kanto T, Kawakami Y, Kimura K. Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget 2019;10:3013-26. [PMID: 31105882 DOI: 10.18632/oncotarget.26892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
368 Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol 2014;8:1140-58. [PMID: 25178978 DOI: 10.1016/j.molonc.2014.07.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
369 Alcántara-Hernández M, Leylek R, Wagar LE, Engleman EG, Keler T, Marinkovich MP, Davis MM, Nolan GP, Idoyaga J. High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity 2017;47:1037-1050.e6. [PMID: 29221729 DOI: 10.1016/j.immuni.2017.11.001] [Cited by in Crossref: 144] [Cited by in F6Publishing: 139] [Article Influence: 28.8] [Reference Citation Analysis]
370 Kong X, Zhang Q, Lai Y, Hu H, Chen X, Hu Y. Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents 2018;28:69-80. [DOI: 10.1080/13543776.2017.1378349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
371 Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi F, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Journal of Thoracic Oncology 2015;10:1726-35. [DOI: 10.1097/jto.0000000000000687] [Cited by in Crossref: 130] [Cited by in F6Publishing: 75] [Article Influence: 18.6] [Reference Citation Analysis]
372 Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, Chisari FV. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83:9652-9662. [PMID: 19625407 DOI: 10.1128/jvi.00867-09] [Cited by in Crossref: 192] [Cited by in F6Publishing: 118] [Article Influence: 14.8] [Reference Citation Analysis]
373 Deng H, Tan S, Gao X, Zou C, Xu C, Tu K, Song Q, Fan F, Huang W, Zhang Z. Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharm Sin B 2020;10:358-73. [PMID: 32082979 DOI: 10.1016/j.apsb.2019.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
374 Quinn JL, Axtell RC. Emerging Role of Follicular T Helper Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Int J Mol Sci 2018;19:E3233. [PMID: 30347676 DOI: 10.3390/ijms19103233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
375 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
376 Arnason J, Avigan D. Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. Immunotherapy 2012;4:1043-51. [PMID: 23148756 DOI: 10.2217/imt.12.118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
377 Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, Moretta L, Moretta A, Bottino C, Castriconi R. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology 2016;5:e1064578. [PMID: 26942080 DOI: 10.1080/2162402X.2015.1064578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
378 Roviello G, D’angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini ND, Sobhani N. Avelumab in gastric cancer. Immunotherapy 2019;11:759-68. [DOI: 10.2217/imt-2019-0011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
379 Sponaas AM, Yang R, Rustad EH, Standal T, Thoresen AS, Dao Vo C, Waage A, Slørdahl TS, Børset M, Sundan A. PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget 2018;9:32024-35. [PMID: 30174794 DOI: 10.18632/oncotarget.25882] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
380 Cao L, Wang X, Li S, Zhi Q, Wang Y, Wang L, Li K, Jiang R. PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. J Cancer 2017;8:3251-60. [PMID: 29158797 DOI: 10.7150/jca.21118] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
381 Huang A, Ma J, Huang L, Yang F, Cheng P. Mechanisms for enhanced antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein. Oncol Lett 2018;15:8505-15. [PMID: 29928322 DOI: 10.3892/ol.2018.8430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
382 Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev 2016;30:189-200. [PMID: 26699946 DOI: 10.1016/j.blre.2015.11.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
383 Mehrvarz Sarshekeh A, Overman MJ, Kopetz S. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol 2018;14:1869-74. [PMID: 29473436 DOI: 10.2217/fon-2017-0696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
384 Zhu Z, Dong W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther 2018;11:1563-70. [PMID: 29593422 DOI: 10.2147/OTT.S160493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
385 Estévez O, Anibarro L, Garet E, Pallares Á, Barcia L, Calviño L, Maueia C, Mussá T, Fdez-Riverola F, Glez-Peña D, Reboiro-Jato M, López-Fernández H, Fonseca NA, Reljic R, González-Fernández Á. An RNA-seq Based Machine Learning Approach Identifies Latent Tuberculosis Patients With an Active Tuberculosis Profile. Front Immunol 2020;11:1470. [PMID: 32760401 DOI: 10.3389/fimmu.2020.01470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
386 [DOI: 10.1101/656462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res 2016;76:1381-90. [PMID: 26719539 DOI: 10.1158/0008-5472.CAN-15-1743] [Cited by in Crossref: 248] [Cited by in F6Publishing: 156] [Article Influence: 35.4] [Reference Citation Analysis]
388 Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016;34:3733-9. [PMID: 27354476 DOI: 10.1200/JCO.2016.67.3467] [Cited by in Crossref: 415] [Cited by in F6Publishing: 227] [Article Influence: 83.0] [Reference Citation Analysis]
389 Conlon C, Pupa L, Reece EM, Chu CK, Yu JZ, Vorstenbosch J, Winocour S. When Benign Becomes Cancer: Malignant Degeneration of Chronic Inflammation. Semin Plast Surg 2021;35:159-63. [PMID: 34526863 DOI: 10.1055/s-0041-1731462] [Reference Citation Analysis]
390 Mikelez-Alonso I, Magadán S, González-Fernández Á, Borrego F. Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity. Adv Drug Deliv Rev 2021;:113860. [PMID: 34237404 DOI: 10.1016/j.addr.2021.113860] [Reference Citation Analysis]
391 Abid H, Khavandi M, Siddiqui N, Panjawatanan P, Patel A. Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. Cureus 2019;11:e5997. [PMID: 31807385 DOI: 10.7759/cureus.5997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
392 Kono Y, Saito H, Miyauchi W, Shimizu S, Murakami Y, Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Nakayama Y, Sakurai C, Hatsuzawa K, Fujiwara Y. Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients. BMC Cancer 2020;20:175. [PMID: 32131763 DOI: 10.1186/s12885-020-6629-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
393 Jiao YM, Yang HG, Huang HH, Tu B, Xing SJ, Mao L, Xia W, He R, Zhang JY, Xu RN, Jin L, Shi M, Xu Z, Qin EQ, Wang XC, Wu H, Ye L, Wang FS. Dichotomous Roles of Programmed Cell Death 1 on HIV-Specific CXCR5+ and CXCR5- CD8+ T Cells during Chronic HIV Infection. Front Immunol 2017;8:1786. [PMID: 29312314 DOI: 10.3389/fimmu.2017.01786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
394 Smolle MA, Calin HN, Pichler M, Calin GA. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. FEBS J 2017;284:1952-66. [PMID: 28132417 DOI: 10.1111/febs.14030] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 13.2] [Reference Citation Analysis]
395 Kasai S, Itonaga H, Niino D, Miyoshi H, Kato T, Imanishi D, Fujioka M, Furumoto T, Sato S, Sawayama Y, Taguchi J, Imaizumi Y, Hata T, Yoshida S, Moriuchi Y, Ohshima K, Miyazaki Y. Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group. Int J Hematol 2020;112:524-34. [PMID: 32588395 DOI: 10.1007/s12185-020-02926-6] [Reference Citation Analysis]
396 Hermansson A, Johansson DK, Ketelhuth DF, Andersson J, Zhou X, Hansson GK. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011;123:1083-91. [PMID: 21357823 DOI: 10.1161/CIRCULATIONAHA.110.973222] [Cited by in Crossref: 137] [Cited by in F6Publishing: 74] [Article Influence: 12.5] [Reference Citation Analysis]
397 Feng C, Cao LJ, Song HF, Xu P, Chen H, Xu JC, Zhu XY, Zhang XG, Wang XF. Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters. Viral Immunol 2015;28:418-24. [PMID: 26266813 DOI: 10.1089/vim.2015.0062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
398 Li Y, Wang J, Li C, Ke XY. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma. 2012;53:2015-2023. [PMID: 22462616 DOI: 10.3109/10428194.2012.673228] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
399 Tang Y, Ma T, Jia S, Zhang Q, Liu S, Qi L, Yang L. The Mechanism of Interleukin-35 in Chronic Hepatitis B. Semin Liver Dis 2021. [PMID: 34233371 DOI: 10.1055/s-0041-1731708] [Reference Citation Analysis]
400 Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and autoimmunity: A growing relationship. Cell Immunol 2016;310:27-41. [PMID: 27660198 DOI: 10.1016/j.cellimm.2016.09.009] [Cited by in Crossref: 115] [Cited by in F6Publishing: 117] [Article Influence: 19.2] [Reference Citation Analysis]
401 Shirjang S, Alizadeh N, Mansoori B, Mahmoodpoor A, Kafil HS, Hojjat-Farsangi M, Yousefi M. Promising immunotherapy: Highlighting cytokine-induced killer cells. J Cell Biochem 2019;120:8863-83. [PMID: 30556298 DOI: 10.1002/jcb.28250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
402 Novotny JF Jr, Cogswell J, Inzunza H, Harbison C, Horak C, Averbuch S. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Ann Oncol 2016;27:1966-9. [PMID: 27502705 DOI: 10.1093/annonc/mdw288] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
403 Monaghan SF, Thakkar RK, Heffernan DS, Huang X, Chung CS, Lomas-Neira J, Cioffi WG, Ayala A. Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. Ann Surg 2012;255:158-64. [PMID: 21997806 DOI: 10.1097/SLA.0b013e31823433ca] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
404 Chang YL, Yang CY, Lin MW, Wu CT, Yang PC. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. Lung Cancer. 2015;88:254-259. [PMID: 25862146 DOI: 10.1016/j.lungcan.2015.03.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
405 Cho YN, Kee SJ, Kim TJ, Jin HM, Kim MJ, Jung HJ, Park KJ, Lee SJ, Lee SS, Kwon YS, Kee HJ, Kim N, Park YW. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. J Immunol. 2014;193:3891-3901. [PMID: 25225673 DOI: 10.4049/jimmunol.1302701] [Cited by in Crossref: 108] [Cited by in F6Publishing: 106] [Article Influence: 13.5] [Reference Citation Analysis]
406 McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46-54. [PMID: 26562159 DOI: 10.1001/jamaoncol.2015.3638] [Cited by in Crossref: 431] [Cited by in F6Publishing: 460] [Article Influence: 71.8] [Reference Citation Analysis]
407 Sham CW, Chan AM, Kwong JM, Caprioli J, Nusinowitz S, Chen B, Lee JG, Gandhi NM, Francisco LM, Sharpe AH, Chen L, Braun J, Gordon LK. Neuronal programmed cell death-1 ligand expression regulates retinal ganglion cell number in neonatal and adult mice. J Neuroophthalmol 2012;32:227-37. [PMID: 22635166 DOI: 10.1097/WNO.0b013e3182589589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
408 Pai SI, Faquin WC. Programmed cell death ligand 1 as a biomarker in head and neck cancer. Cancer Cytopathol 2017;125:529-33. [PMID: 28472542 DOI: 10.1002/cncy.21872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
409 Simon B, Uslu U. CAR-T cell therapy in melanoma: A future success story? Exp Dermatol 2018;27:1315-21. [PMID: 30288790 DOI: 10.1111/exd.13792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
410 Blumenfeld HJ, Tohn R, Haeryfar SM, Liu Y, Savage PB, Delovitch TL. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 2011;166:121-33. [PMID: 21910729 DOI: 10.1111/j.1365-2249.2011.04454.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
411 Cheng M, Hung M, Song J, Lin S, Liao F, Wu M, Hsiao W, Hsieh C, Wu J, Chao Y, Shih C, Wu S, Ueng S. Discovery and structure–activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. Bioorganic & Medicinal Chemistry Letters 2014;24:3403-6. [DOI: 10.1016/j.bmcl.2014.05.084] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
412 Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, Larsen M, Pancino G, Douek DC, Autran B, Sáez-Cirión A, Appay V. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009;113:6351-60. [PMID: 19389882 DOI: 10.1182/blood-2009-02-206557] [Cited by in Crossref: 164] [Cited by in F6Publishing: 158] [Article Influence: 12.6] [Reference Citation Analysis]
413 Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214-2219. [PMID: 25211661 DOI: 10.1038/bjc.2014.348] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
414 Zhang Y, Wang Y, Jiang Y, Pan W, Liu H, Yin J, Shen Y, Cao J. T follicular helper cells in patients with acute schistosomiasis. Parasit Vectors 2016;9:321. [PMID: 27266984 DOI: 10.1186/s13071-016-1602-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
415 Miao X, Xu R, Fan B, Chen J, Li X, Mao W, Hua S, Li B. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Sci Rep 2018;8:1605. [PMID: 29371688 DOI: 10.1038/s41598-018-19407-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
416 Jang BS, Kim IA. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. Radiother Oncol 2017;124:403-10. [PMID: 28579282 DOI: 10.1016/j.radonc.2017.05.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
417 Hanna KS. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. Pharmacotherapy 2017;37:1391-405. [PMID: 28950037 DOI: 10.1002/phar.2033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
418 Golrokh Mofrad M, Taghizadeh Maleki D, Faghihloo E. The roles of programmed death ligand 1 in virus-associated cancers. Infection, Genetics and Evolution 2020;84:104368. [DOI: 10.1016/j.meegid.2020.104368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
419 Fleisher B, Clarke C, Ait-Oudhia S. Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press) 2016;8:183-97. [PMID: 27785100 DOI: 10.2147/BCTT.S114659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
420 Kamal Y, Schmit SL, Hoehn HJ, Amos CI, Frost HR. Transcriptomic Differences between Primary Colorectal Adenocarcinomas and Distant Metastases Reveal Metastatic Colorectal Cancer Subtypes. Cancer Res 2019;79:4227-41. [PMID: 31239274 DOI: 10.1158/0008-5472.CAN-18-3945] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
421 Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Gandhi J, Santandrea G, Bonacini M. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). Int J Mol Sci 2021;22:12297. [PMID: 34830179 DOI: 10.3390/ijms222212297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
422 Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537-1544. [PMID: 19423728 DOI: 10.1182/blood-2008-12-195792] [Cited by in Crossref: 964] [Cited by in F6Publishing: 910] [Article Influence: 74.2] [Reference Citation Analysis]
423 Chen DS, Hurwitz H. Combinations of Bevacizumab With Cancer Immunotherapy. Cancer J. 2018;24:193-204. [PMID: 30119083 DOI: 10.1097/ppo.0000000000000327] [Cited by in Crossref: 67] [Cited by in F6Publishing: 33] [Article Influence: 22.3] [Reference Citation Analysis]
424 Boer MC, van Meijgaarden KE, Goletti D, Vanini V, Prins C, Ottenhoff TH, Joosten SA. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. Tuberculosis (Edinb) 2016;97:163-71. [PMID: 26750180 DOI: 10.1016/j.tube.2015.11.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
425 Chang SY, Cha HR, Chang JH, Ko HJ, Yang H, Malissen B, Iwata M, Kweon MN. Lack of retinoic acid leads to increased langerin-expressing dendritic cells in gut-associated lymphoid tissues. Gastroenterology 2010;138:1468-78, 1478.e1-6. [PMID: 19914251 DOI: 10.1053/j.gastro.2009.11.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
426 Hong BJ, Kim J, Jeong H, Bok S, Kim YE, Ahn GO. Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy. Radiat Oncol J 2016;34:239-49. [PMID: 28030900 DOI: 10.3857/roj.2016.02012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
427 Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol 2015;42:363-77. [PMID: 25965355 DOI: 10.1053/j.seminoncol.2015.02.015] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 11.0] [Reference Citation Analysis]
428 Hughes T, Klairmont M, Sharfman WH, Kaufman HL. Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma. Cancer Biology & Therapy 2017. [DOI: 10.1080/15384047.2015.1095401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
429 Yan Y, Gao R, Trinh TLP, Grant MB. Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics. Clin Cancer Res 2017;23:6363-73. [PMID: 28684632 DOI: 10.1158/1078-0432.CCR-17-0250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
430 Ooft ML, van Ipenburg JA, Braunius WW, Zuur CI, Koljenović S, Willems SM. Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma. Oral Oncol 2017;71:16-25. [PMID: 28688685 DOI: 10.1016/j.oraloncology.2017.05.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
431 Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) 2015;240:1087-98. [PMID: 25956686 DOI: 10.1177/1535370215584936] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
432 Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118:2659-69. [PMID: 21700770 DOI: 10.1182/blood-2011-05-326538] [Cited by in Crossref: 137] [Cited by in F6Publishing: 120] [Article Influence: 12.5] [Reference Citation Analysis]
433 Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res 2016;76:2525-39. [PMID: 26980767 DOI: 10.1158/0008-5472.CAN-15-1293] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]
434 Ogawa K, Kozuka Y, Uno H, Utsumi K, Noyori O, Hosoki R. Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database. Clin Drug Investig 2021;41:615-27. [PMID: 34110613 DOI: 10.1007/s40261-021-01042-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Ankri C, Shamalov K, Horovitz-fried M, Mauer S, Cohen CJ. Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. J I 2013;191:4121-9. [DOI: 10.4049/jimmunol.1203085] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
436 Bao X, Shi R, Zhang K, Xin S, Li X, Zhao Y, Wang Y. Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature. Front Oncol 2019;9:903. [PMID: 31620363 DOI: 10.3389/fonc.2019.00903] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
437 Henson SM, Akbar AN. Memory T-Cell Homeostasis and Senescence during Aging. In: Zanetti M, Schoenberger SP, editors. Memory T Cells. New York: Springer; 2010. pp. 189-97. [DOI: 10.1007/978-1-4419-6451-9_15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
438 Garcia V, Bonhoeffer S, Fu F. Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: A mathematical and computational examination. J Theor Biol 2020;492:110185. [PMID: 32035826 DOI: 10.1016/j.jtbi.2020.110185] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
439 Esen F, Deniz G, Aktas EC. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. Immunol Lett 2021;240:15-23. [PMID: 34599946 DOI: 10.1016/j.imlet.2021.09.009] [Reference Citation Analysis]
440 Wang Y, Bhave MS, Yagita H, Cardell SL. Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer. Front Immunol 2020;11:581301. [PMID: 33193386 DOI: 10.3389/fimmu.2020.581301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
441 Kowalski A, Malinowska K, Olszewski J, Zielińska-Bliźniewska H. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer. Biomolecules 2021;11:970. [PMID: 34356594 DOI: 10.3390/biom11070970] [Reference Citation Analysis]
442 Joest B, Kempf W, Berisha A, Peyk P, Tronnier M, Mitteldorf C. Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment. J Cutan Pathol 2020;47:888-95. [PMID: 32310306 DOI: 10.1111/cup.13716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Roussey JA, Olszewski MA, Osterholzer JJ. Immunoregulation in Fungal Diseases. Microorganisms 2016;4:E47. [PMID: 27973396 DOI: 10.3390/microorganisms4040047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
444 Wang X, Wu Z, Qiu W, Chen P, Xu X, Han W. Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system. Front Med 2020;14:726-45. [PMID: 32794014 DOI: 10.1007/s11684-020-0746-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
445 Zinselmeyer BH, Heydari S, Sacristán C, Nayak D, Cammer M, Herz J, Cheng X, Davis SJ, Dustin ML, McGavern DB. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013;210:757-74. [PMID: 23530125 DOI: 10.1084/jem.20121416] [Cited by in Crossref: 155] [Cited by in F6Publishing: 151] [Article Influence: 17.2] [Reference Citation Analysis]
446 Petrelli A, van Wijk F. CD8(+) T cells in human autoimmune arthritis: the unusual suspects. Nat Rev Rheumatol 2016;12:421-8. [PMID: 27256711 DOI: 10.1038/nrrheum.2016.74] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
447 Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 2012;120:728-36. [DOI: 10.1182/blood-2012-02-412510] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
448 Furtado R, Chorro L, Zimmerman N, Guillen E, Spaulding E, Chin SS, Daily JP, Lauvau G. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses. Front Immunol 2020;11:576743. [PMID: 33519801 DOI: 10.3389/fimmu.2020.576743] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
449 Niavarani A, Shahrabi Farahani A, Sharafkhah M, Rassoulzadegan M. Pancancer analysis identifies prognostic high-APOBEC1 expression level implicated in cancer in-frame insertions and deletions. Carcinogenesis 2018;39:327-35. [PMID: 29346513 DOI: 10.1093/carcin/bgy005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
450 Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer 2018;124:248-61. [PMID: 29211297 DOI: 10.1002/cncr.31105] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
451 Zhu C, Dai Y, Zhang H, Ruan Y, Zhou Y, Dai Y, Fan L, Jia T, Lu H, Chen Q. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis. Diagn Pathol 2021;16:84. [PMID: 34465342 DOI: 10.1186/s13000-021-01139-7] [Reference Citation Analysis]
452 Li S, Liao W, Chen M, Shan S, Song Y, Zhang S, Song H, Yuan Z. Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis. Inflammation 2014;37:116-21. [DOI: 10.1007/s10753-013-9718-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
453 de la Fuente-Granada M, Olguín-Alor R, Ortega-Francisco S, Bonifaz LC, Soldevila G. Inhibins regulate peripheral regulatory T cell induction through modulation of dendritic cell function. FEBS Open Bio 2019;9:137-47. [PMID: 30652081 DOI: 10.1002/2211-5463.12555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
454 Dorneles GP, da Silva IM, Santos MA, Elsner VR, Fonseca SG, Peres A, Romão PRT. Immunoregulation induced by autologous serum collected after acute exercise in obese men: a randomized cross-over trial. Sci Rep 2020;10:21735. [PMID: 33303928 DOI: 10.1038/s41598-020-78750-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
455 Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, Song J, Wang J, Wei H, Zhang J, Sun R, Zhang C, Tian Z. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun 2018;9:1241. [PMID: 29593314 DOI: 10.1038/s41467-018-03584-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
456 Liu X, Hu LH, Li YR, Chen FH, Ning Y, Yao QF. Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatol Int 2011;31:209-13. [PMID: 20012629 DOI: 10.1007/s00296-009-1264-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
457 Chipollini J, da Costa WH, Werneck da Cunha I, de Almeida E Paula F, Guilherme O Salles P, Azizi M, Spiess PE, Abreu D, Zequi SC. Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Ther Adv Urol 2019;11:1756287219882600. [PMID: 31662794 DOI: 10.1177/1756287219882600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
458 Papageorgiou SG, Thomopoulos TP, Katagas I, Bouchla A, Pappa V. Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications. Ther Adv Hematol 2021;12:20406207211013987. [PMID: 34104369 DOI: 10.1177/20406207211013987] [Reference Citation Analysis]
459 Yassin M, Sadowska Z, Djurhuus D, Nielsen B, Tougaard P, Olsen J, Pedersen AE. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice. Immunology 2019;158:35-46. [PMID: 31429085 DOI: 10.1111/imm.13093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
460 Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29:71-83. [PMID: 29069302 DOI: 10.1093/annonc/mdx686] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 37.3] [Reference Citation Analysis]
461 Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol 2014;7:58. [PMID: 25355407 DOI: 10.1186/s13045-014-0058-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
462 Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328 [PMID: 28848698 DOI: 10.5306/wjco.v8.i4.320] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
463 Ramelyte E, Schindler SA, Dummer R. The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opin Drug Saf 2017;16:41-53. [PMID: 27737598 DOI: 10.1080/14740338.2016.1248402] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
464 Chen H, Moussa M, Catalfamo M. The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure? Front Immunol 2020;11:1223. [PMID: 32714317 DOI: 10.3389/fimmu.2020.01223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
465 Qiu H, Zheng L, Tang W, Yin P, Cheng F, Wang L. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clinical Biochemistry 2014;47:612-7. [DOI: 10.1016/j.clinbiochem.2013.12.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
466 Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199-4206. [PMID: 24127452 DOI: 10.1200/jco.2012.48.3685] [Cited by in Crossref: 335] [Cited by in F6Publishing: 175] [Article Influence: 37.2] [Reference Citation Analysis]
467 Liao X, Zhao L, Wu S, Zheng H, Chen H, Zhang H, Wang Z, Lin Q. Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. Oncotarget 2017;8:113287-93. [PMID: 29348907 DOI: 10.18632/oncotarget.22938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
468 王维嘉, 王丹, 秦国慧, 陈新峰, 张毅. 免疫检查点抑制剂在结直肠癌中的应用以及未来发展方向. 世界华人消化杂志 2017; 25(19): 1714-1727 [DOI: 10.11569/wcjd.v25.i19.1714] [Reference Citation Analysis]
469 Yang WC, Lin SF. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int 2015;2015:341430. [PMID: 26649299 DOI: 10.1155/2015/341430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
470 Bonavida B, Chouaib S. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. Ann Oncol 2017;28:457-67. [PMID: 27864216 DOI: 10.1093/annonc/mdw615] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
471 Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis 2017;56:221-8. [PMID: 28163164 DOI: 10.1016/j.ijid.2017.01.028] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 14.0] [Reference Citation Analysis]
472 Peng Y. Forced expression of IL-7R promotes CD8 T cell cytotoxicity to self antigen. PLoS One 2017;12:e0188112. [PMID: 29272267 DOI: 10.1371/journal.pone.0188112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
473 Kim JE, Patel K, Jackson CM. The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. Expert Opin Ther Targets 2021;25:101-13. [PMID: 33356658 DOI: 10.1080/14728222.2021.1869213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
474 Bhandaru M, Rotte A. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. Methods Mol Biol 2019;1904:83-108. [PMID: 30539467 DOI: 10.1007/978-1-4939-8958-4_4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
475 Patil NK, Guo Y, Luan L, Sherwood ER. Targeting Immune Cell Checkpoints during Sepsis. Int J Mol Sci 2017;18:E2413. [PMID: 29135922 DOI: 10.3390/ijms18112413] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 13.0] [Reference Citation Analysis]
476 Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Front Immunol 2019;10:1337. [PMID: 31258527 DOI: 10.3389/fimmu.2019.01337] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 16.7] [Reference Citation Analysis]
477 He Y, Lei L, Cao J, Yang X, Cai S, Tong F, Huang D, Mei H, Luo K, Gao H, He B, Peppas NA. A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. Sci Adv 2021;7:eaba0776. [PMID: 33547067 DOI: 10.1126/sciadv.aba0776] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
478 Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286-94. [PMID: 20460501 DOI: 10.1182/blood-2010-02-271874] [Cited by in Crossref: 512] [Cited by in F6Publishing: 498] [Article Influence: 42.7] [Reference Citation Analysis]
479 Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014;211:943-959. [PMID: 24752301 DOI: 10.1016/j.molimm.2010.12.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
480 Yu X, Pan Y, Fei Q, Lin X, Chen Z, Huang H. Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis. Immun Inflamm Dis 2021;9:310-8. [PMID: 33417300 DOI: 10.1002/iid3.394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
481 Mukalel AJ, Riley RS, Zhang R, Mitchell MJ. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy. Cancer Lett 2019;458:102-12. [PMID: 31100411 DOI: 10.1016/j.canlet.2019.04.040] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
482 Krishnamoorthy S, Liu T, Drager D, Patarroyo-White S, Chhabra ES, Peters R, Josephson N, Lillicrap D, Blumberg RS, Pierce GF, Jiang H. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol 2016;301:30-9. [PMID: 26775174 DOI: 10.1016/j.cellimm.2015.12.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
483 Meza Guzman LG, Keating N, Nicholson SE. Natural Killer Cells: Tumor Surveillance and Signaling. Cancers (Basel) 2020;12:E952. [PMID: 32290478 DOI: 10.3390/cancers12040952] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
484 Chen G, Kim YH, Li H, Luo H, Liu DL, Zhang ZJ, Lay M, Chang W, Zhang YQ, Ji RR. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 2017;20:917-26. [PMID: 28530662 DOI: 10.1038/nn.4571] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 15.2] [Reference Citation Analysis]
485 Jacquelot N, Ghaedi M, Warner K, Chung DC, Crome SQ, Ohashi PS. Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers (Basel) 2021;13:5967. [PMID: 34885076 DOI: 10.3390/cancers13235967] [Reference Citation Analysis]
486 Ilkovitch D, Lopez DM. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009;69:5514-21. [PMID: 19549903 DOI: 10.1158/0008-5472.CAN-08-4625] [Cited by in Crossref: 120] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
487 Wang HC, Hung WC, Chen LT, Pan MR. From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. Int J Mol Sci 2018;19:E3584. [PMID: 30428588 DOI: 10.3390/ijms19113584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
488 Lian G, Arimochi H, Kitamura A, Nishida J, Li S, Kishihara K, Maekawa Y, Yasutomo K. Manipulation of CD98 resolves type 1 diabetes in nonobese diabetic mice. J Immunol 2012;188:2227-34. [PMID: 22291182 DOI: 10.4049/jimmunol.1102586] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
489 Johnson RMG, Wen T, Dong H. Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nat Immunol 2020;21:365-6. [PMID: 32152507 DOI: 10.1038/s41590-020-0599-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
490 Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870. [PMID: 24349382 DOI: 10.1371/journal.pone.0082870] [Cited by in Crossref: 175] [Cited by in F6Publishing: 182] [Article Influence: 19.4] [Reference Citation Analysis]
491 Ramamurthy C, Godwin JL, Borghaei H. Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose? Curr Treat Options Oncol 2017;18:33. [PMID: 28534248 DOI: 10.1007/s11864-017-0476-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
492 Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77. [PMID: 24332512 DOI: 10.1016/S1470-2045(13)70551-5] [Cited by in Crossref: 382] [Cited by in F6Publishing: 201] [Article Influence: 42.4] [Reference Citation Analysis]
493 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
494 Hung AL, Garzon-Muvdi T, Lim M. Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurg 2017;102:494-506. [PMID: 28300714 DOI: 10.1016/j.wneu.2017.03.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
495 Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013;19:4917-4924. [PMID: 23868869 DOI: 10.1158/1078-0432.ccr-12-1972] [Cited by in Crossref: 160] [Cited by in F6Publishing: 102] [Article Influence: 17.8] [Reference Citation Analysis]
496 Wolchinsky R, Hod-Marco M, Oved K, Shen-Orr SS, Bendall SC, Nolan GP, Reiter Y. Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes. J Immunol 2014;192:2109-19. [PMID: 24489091 DOI: 10.4049/jimmunol.1301142] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
497 Li X, Deng R, He W, Liu C, Wang M, Young J, Meng Z, Du C, Huang W, Chen L, Chen Y, Martin P, Forman S, Zeng D. Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease. J Immunol 2012;188:724-34. [PMID: 22156590 DOI: 10.4049/jimmunol.1102630] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
498 Calabretta E, Carlo-Stella C. The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. Cells 2020;9:E802. [PMID: 32225002 DOI: 10.3390/cells9040802] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
499 Garcia-Bates TM, Palma ML, Shen C, Gambotto A, Macatangay BJC, Ferris RL, Rinaldo CR, Mailliard RB. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions. J Virol 2019;93:e02035-18. [PMID: 30541848 DOI: 10.1128/JVI.02035-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
500 Mony JT, Zhang L, Ma T, Grabosch S, Tirodkar TS, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang X, Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunol Immunother 2015;64:1095-108. [PMID: 25998800 DOI: 10.1007/s00262-015-1712-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
501 Safi M, Ahmed H, Al-Azab M, Xia YL, Shan X, Al-Radhi M, Al-Danakh A, Shopit A, Liu J. PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. J Adv Res 2021;29:45-54. [PMID: 33842004 DOI: 10.1016/j.jare.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Ann Surg Oncol 2019;26:1916-24. [PMID: 30815801 DOI: 10.1245/s10434-019-07231-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
503 Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci 2020;21:E6885. [PMID: 32961800 DOI: 10.3390/ijms21186885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
504 Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. Tumor Neovascularization and Developments in Therapeutics. Cancers (Basel) 2019;11:E316. [PMID: 30845711 DOI: 10.3390/cancers11030316] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
505 Largeot A, Pagano G, Gonder S, Moussay E, Paggetti J. The B-side of Cancer Immunity: The Underrated Tune. Cells 2019;8:E449. [PMID: 31086070 DOI: 10.3390/cells8050449] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
506 Rotman J, den Otter LAS, Bleeker MCG, Samuels SS, Heeren AM, Roemer MGM, Kenter GG, Zijlmans HJMAA, van Trommel NE, de Gruijl TD, Jordanova ES. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Front Immunol 2020;11:596825. [PMID: 33424844 DOI: 10.3389/fimmu.2020.596825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
507 Qiao XW, Jiang J, Pang X, Huang MC, Tang YJ, Liang XH, Tang YL. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Front Immunol 2020;11:1721. [PMID: 33072064 DOI: 10.3389/fimmu.2020.01721] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
508 Al-Chaqmaqchi H, Sadeghi B, Abedi-Valugerdi M, Al-Hashmi S, Fares M, Kuiper R, Lundahl J, Hassan M, Moshfegh A. The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. PLoS One 2013;8:e60367. [PMID: 23593203 DOI: 10.1371/journal.pone.0060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
509 Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38:1-11. [PMID: 25415283 DOI: 10.1097/cji.0000000000000062] [Cited by in Crossref: 232] [Cited by in F6Publishing: 176] [Article Influence: 33.1] [Reference Citation Analysis]
510 Khedr S, Enwereuzo CL, Secola S, Mai N, Miron P, Hutchinson L, Chen B. Plasmablastic lymphoma presenting as a soft tissue mass associated with a chronic wound in an immunocompetent patient. J Hematopathol 2020;13:279-85. [DOI: 10.1007/s12308-020-00408-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
511 Zahran AM, Hetta HF, Rayan A, Eldin AS, Hassan EA, Fakhry H, Soliman A, El-Badawy O. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes. Cancer Immunol Immunother. 2020;69:1253-1263. [PMID: 32170378 DOI: 10.1007/s00262-019-02465-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
512 Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol 2021;5:10. [PMID: 33580183 DOI: 10.1038/s41698-021-00147-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
513 Okamura T, Yamamoto K, Fujio K. Early Growth Response Gene 2-Expressing CD4+LAG3+ Regulatory T Cells: The Therapeutic Potential for Treating Autoimmune Diseases. Front Immunol 2018;9:340. [PMID: 29535721 DOI: 10.3389/fimmu.2018.00340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
514 Breton G, Yassine-Diab B, Cohn L, Boulassel MR, Routy JP, Sékaly RP, Steinman RM. siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals. J Clin Immunol 2009;29:637-45. [PMID: 19562472 DOI: 10.1007/s10875-009-9313-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
515 Badiyan SN, Roach MC, Chuong MD, Rice SR, Onyeuku NE, Remick J, Chilukuri S, Glass E, Mohindra P, Simone CB 2nd. Combining immunotherapy with radiation therapy in thoracic oncology. J Thorac Dis 2018;10:S2492-507. [PMID: 30206494 DOI: 10.21037/jtd.2018.05.73] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
516 Li WX, Xu XH, Jin LP. Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective. J Cell Mol Med 2021;25:10362-75. [PMID: 34708495 DOI: 10.1111/jcmm.17022] [Reference Citation Analysis]
517 O'Donnell EK, Raje NS. New monoclonal antibodies on the horizon in multiple myeloma. Ther Adv Hematol 2017;8:41-53. [PMID: 28203341 DOI: 10.1177/2040620716682490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
518 Mohammadi R, Aryan A, Omrani MD, Ghaderian SMH, Fazeli Z. Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis. Biologics 2021;15:53-9. [PMID: 33688164 DOI: 10.2147/BTT.S267277] [Reference Citation Analysis]
519 Gatteschi L, Iannopollo M, Gonfiotti A. Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review. Life (Basel) 2021;11:1036. [PMID: 34685407 DOI: 10.3390/life11101036] [Reference Citation Analysis]
520 Liu D, Badeti S, Dotti G, Jiang JG, Wang H, Dermody J, Soteropoulos P, Streck D, Birge RB, Liu C. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Commun Signal 2020;18:134. [PMID: 32843053 DOI: 10.1186/s12964-020-00617-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
521 Prell RA, Halpern WG, Rao GK. Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy. Int J Toxicol 2016;35:263-73. [DOI: 10.1177/1091581815625596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
522 Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, Kato Y, Fagarasan S, Muramatsu M, Eto T, Hioki K, Honjo T. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med 2011;208:395-407. [PMID: 21300912 DOI: 10.1084/jem.20100466] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 14.5] [Reference Citation Analysis]
523 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016;21:462-73. [DOI: 10.1007/s10147-016-0959-z] [Reference Citation Analysis]
524 Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:39. [PMID: 29769148 DOI: 10.1186/s40425-018-0349-3] [Cited by in Crossref: 139] [Cited by in F6Publishing: 138] [Article Influence: 34.8] [Reference Citation Analysis]
525 Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-9. [PMID: 24548766 DOI: 10.1016/j.ejca.2014.01.018] [Cited by in Crossref: 194] [Cited by in F6Publishing: 217] [Article Influence: 24.3] [Reference Citation Analysis]
526 Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 2015;12:14. [PMID: 25756928 DOI: 10.1186/s12977-015-0144-x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 91] [Article Influence: 12.3] [Reference Citation Analysis]
527 Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 2013;8:e60186. [PMID: 23555918 DOI: 10.1371/journal.pone.0060186] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
528 Takamura S, Tsuji-kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, Kato M, Miyazawa M. Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8 + T Cells by Rapid Induction of Multiple Inhibitory Receptors. J I 2010;184:4696-707. [DOI: 10.4049/jimmunol.0903478] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.0] [Reference Citation Analysis]
529 Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ. Biology and treatment of myeloma. Clin Lymphoma Myeloma Leuk 2014;14 Suppl:S65-70. [PMID: 25486959 DOI: 10.1016/j.clml.2014.06.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
530 Zheng L, Li D, Wang F, Wu H, Li X, Fu J, Chen X, Wang L, Liu Y, Wang S. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J Clin Immunol. 2010;30:855-860. [PMID: 20700634 DOI: 10.1007/s10875-010-9450-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
531 Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. Onco Targets Ther 2019;12:9527-38. [PMID: 31807028 DOI: 10.2147/OTT.S224013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
532 Zhou ZY, Liu SR, Xu LB, Liu C, Zhang R. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis. J Clin Transl Hepatol 2021;9:889-97. [PMID: 34966652 DOI: 10.14218/JCTH.2021.00056] [Reference Citation Analysis]
533 Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 2012;10:67-83. [PMID: 22482468 DOI: 10.1016/j.jtos.2012.01.005] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 9.9] [Reference Citation Analysis]
534 Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M. Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines 2018;6:E26. [PMID: 29494517 DOI: 10.3390/biomedicines6010026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
535 Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 2018;18:91-104. [PMID: 28990586 DOI: 10.1038/nri.2017.112] [Cited by in Crossref: 187] [Cited by in F6Publishing: 183] [Article Influence: 37.4] [Reference Citation Analysis]
536 von Rossum A, Laher I, Choy JC. Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis. Front Immunol 2014;5:684. [PMID: 25628623 DOI: 10.3389/fimmu.2014.00684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
537 Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy 2017;9:797-804. [PMID: 28877632 DOI: 10.2217/imt-2017-0042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
538 Liu C, Seeram NP, Ma H. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell Int 2021;21:239. [PMID: 33906641 DOI: 10.1186/s12935-021-01946-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
539 Wilden SM, Lang BM, Mohr P, Grabbe S. Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. J Dtsch Dermatol Ges 2016;14:685-97. [PMID: 27373243 DOI: 10.1111/ddg.13012_g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
540 Young JS, Wu T, Chen Y, Zhao D, Liu H, Yi T, Johnston H, Racine J, Li X, Wang A, Todorov I, Zeng D. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol 2012;189:222-33. [PMID: 22649197 DOI: 10.4049/jimmunol.1200677] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
541 Peyraud F, Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers (Basel) 2020;12:E1502. [PMID: 32526888 DOI: 10.3390/cancers12061502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
542 Hashemi M, Karami S, Sarabandi S, Moazeni-Roodi A, Małecki A, Ghavami S, Wiechec E. Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies. Cancers (Basel) 2019;11:E1150. [PMID: 31405171 DOI: 10.3390/cancers11081150] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
543 Kunitomi H, Banno K, Yanokura M, Takeda T, Iijima M, Nakamura K, Iida M, Adachi M, Watanabe K, Matoba Y, Kobayashi Y, Tominaga E, Aoki D. New use of microsatellite instability analysis in endometrial cancer. Oncol Lett 2017;14:3297-301. [PMID: 28927079 DOI: 10.3892/ol.2017.6640] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
544 Konishi CT, Long C. Progress and challenges in CRISPR-mediated therapeutic genome editing for monogenic diseases. J Biomed Res 2020;35:148-62. [PMID: 33402545 DOI: 10.7555/JBR.34.20200105] [Reference Citation Analysis]
545 Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090. [PMID: 26822379 DOI: 10.1038/srep20090] [Cited by in Crossref: 95] [Cited by in F6Publishing: 106] [Article Influence: 15.8] [Reference Citation Analysis]
546 Hu G, Feng Y, O’hara SP, Chen X. Immunology of Cryptosporidiosis. In: Cacciò SM, Widmer G, editors. Cryptosporidium: parasite and disease. Vienna: Springer; 2014. pp. 423-54. [DOI: 10.1007/978-3-7091-1562-6_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
547 Mestrallet G, Auvré F, Schenowitz C, Carosella ED, LeMaoult J, Martin MT, Rouas-Freiss N, Fortunel NO. Human Keratinocytes Inhibit CD4+ T-Cell Proliferation through TGFB1 Secretion and Surface Expression of HLA-G1 and PD-L1 Immune Checkpoints. Cells 2021;10:1438. [PMID: 34201301 DOI: 10.3390/cells10061438] [Reference Citation Analysis]
548 Seth A, Oh DB, Lim YT. Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine. Nanomedicine (Lond) 2015;10:959-75. [PMID: 25867860 DOI: 10.2217/nnm.14.200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
549 Hotta K, Fujimoto N. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. J Immunother Cancer 2020;8:e000461. [PMID: 32098830 DOI: 10.1136/jitc-2019-000461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
550 Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34:2460-2467. [PMID: 27138582 DOI: 10.1200/jco.2015.64.8931] [Cited by in Crossref: 707] [Cited by in F6Publishing: 427] [Article Influence: 117.8] [Reference Citation Analysis]
551 Zhang W, Shen H, Zhang Y, Wang W, Hu S, Zou D, Zhou D. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells. Cancer Med 2019;8:2104-13. [PMID: 30969023 DOI: 10.1002/cam4.2097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
552 Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy. Mol Ther 2021;29:908-19. [PMID: 33388422 DOI: 10.1016/j.ymthe.2020.12.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
553 Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? Cancer Treat Rev. 2016;48:61-68. [PMID: 27362548 DOI: 10.1016/j.ctrv.2016.06.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 11.8] [Reference Citation Analysis]
554 Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 2017;66:877-90. [PMID: 28349165 DOI: 10.1007/s00262-017-1987-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 14.8] [Reference Citation Analysis]
555 Passaro A, Mancuso P, Gandini S, Spitaleri G, Labanca V, Guerini-Rocco E, Barberis M, Catania C, Del Signore E, de Marinis F, Bertolini F. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. Clin Transl Oncol 2020;22:603-11. [PMID: 31254252 DOI: 10.1007/s12094-019-02166-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
556 Sun NY, Chen YL, Wu WY, Lin HW, Chiang YC, Chang CF, Tai YJ, Hsu HC, Chen CA, Sun WZ, Cheng WF. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. Cancers (Basel) 2019;11:E1400. [PMID: 31546897 DOI: 10.3390/cancers11091400] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
557 Ju A, Lee SW, Lee YE, Han KC, Kim JC, Shin SC, Park HJ, EunKyeong Kim E, Hong S, Jang M. A carrier-free multiplexed gene editing system applicable for suspension cells. Biomaterials 2019;217:119298. [PMID: 31280073 DOI: 10.1016/j.biomaterials.2019.119298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
558 Ansell SM. Checkpoint Blockade in Lymphoma. JCO 2021;39:525-33. [DOI: 10.1200/jco.20.01522] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
559 Ruiz P, Maldonado P, Hidalgo Y, Gleisner A, Sauma D, Silva C, Saez JJ, Nuñez S, Rosemblatt M, Bono MR. Transplant tolerance: new insights and strategies for long-term allograft acceptance. Clin Dev Immunol 2013;2013:210506. [PMID: 23762087 DOI: 10.1155/2013/210506] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
560 Shang M, Chang C, Pei Y, Guan Y, Chang J, Li H. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. J Cancer 2018;9:4627-34. [PMID: 30588246 DOI: 10.7150/jca.28458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
561 Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH, Ploegh HL, Dougan SK. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Cancer Immunol Res 2018;6:389-401. [PMID: 29459478 DOI: 10.1158/2326-6066.CIR-17-0495] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
562 Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem 2019;62:1715-30. [PMID: 30247903 DOI: 10.1021/acs.jmedchem.8b00990] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
563 Di Scala M, Otano I, Gil-Fariña I, Vanrell L, Hommel M, Olagüe C, Vales A, Galarraga M, Guembe L, Ortiz de Solorzano C, Ghosh I, Maini MK, Prieto J, González-Aseguinolaza G. Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. J Virol 2016;90:8563-74. [PMID: 27440883 DOI: 10.1128/JVI.01030-16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
564 Msaouel P, Massarelli E. Immune Checkpoint Therapy in Head and Neck Cancers. The Cancer Journal 2016;22:108-16. [DOI: 10.1097/ppo.0000000000000180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
565 Qiu M, Chen Y, Ye Q. Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity. BMC Pulm Med 2021;21:175. [PMID: 34022844 DOI: 10.1186/s12890-021-01531-5] [Reference Citation Analysis]
566 Du L, Lin L, Li Q, Liu K, Huang Y, Wang X, Cao K, Chen X, Cao W, Li F, Shao C, Wang Y, Shi Y. IGF-2 Preprograms Maturing Macrophages to Acquire Oxidative Phosphorylation-Dependent Anti-inflammatory Properties. Cell Metab 2019;29:1363-1375.e8. [PMID: 30745181 DOI: 10.1016/j.cmet.2019.01.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
567 Wei M, Liu X, Cao C, Yang J, Lv Y, Huang J, Wang Y, Qin Y. An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Rep 2018;51:572-7. [DOI: 10.5483/bmbrep.2018.51.11.076] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
568 Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, Kim CH. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther 2021:S1525-0016(21)00498-6. [PMID: 34628052 DOI: 10.1016/j.ymthe.2021.10.004] [Reference Citation Analysis]
569 Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Protein Cell 2017;8:861-77. [PMID: 28488245 DOI: 10.1007/s13238-017-0415-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
570 Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol 2017;139:335-346.e3. [PMID: 27372564 DOI: 10.1016/j.jaci.2016.04.025] [Cited by in Crossref: 235] [Cited by in F6Publishing: 235] [Article Influence: 39.2] [Reference Citation Analysis]
571 Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D, Min W. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget 2016;7:53735-50. [PMID: 27447564 DOI: 10.18632/oncotarget.10731] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 13.5] [Reference Citation Analysis]
572 Banck JC, Mueller N, Mellinghoff SC, Thelen M, Fraccaroli A, Blumenberg V, Koehler P, Kunz WG, Rudelius M, Schrötzlmair F, Subklewe M, Schlößer HA, Tischer J, Cornely OA, Lindner LH, von Bergwelt-Baildon M. Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection. Hemasphere 2021;5:e530. [PMID: 33604513 DOI: 10.1097/HS9.0000000000000530] [Reference Citation Analysis]
573 Cho KA, Park M, Kim YH, Ryu KH, Woo SY. Poly I:C primes the suppressive function of human palatine tonsil-derived MSCs against Th17 differentiation by increasing PD-L1 expression. Immunobiology 2017;222:394-8. [PMID: 27594385 DOI: 10.1016/j.imbio.2016.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
574 Greisen SR, Deleuran B. Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted. Curr Rheumatol Rep 2021;23:22. [PMID: 33651184 DOI: 10.1007/s11926-021-00991-2] [Reference Citation Analysis]
575 Kujan O, Agag M, Smaga M, Vaishnaw Y, Idrees M, Shearston K, Farah CS. PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma. Pathology 2021:S0031-3025(21)00523-7. [PMID: 34872754 DOI: 10.1016/j.pathol.2021.09.013] [Reference Citation Analysis]
576 Matsumoto M, Takeda Y, Tatematsu M, Seya T. Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Front Immunol 2017;8:1897. [PMID: 29312355 DOI: 10.3389/fimmu.2017.01897] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
577 Akella P, Loganathan S, Jindal V, Akhtar J, Lal A. Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. Respir Med Case Rep 2019;26:17-22. [PMID: 30456167 DOI: 10.1016/j.rmcr.2018.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
578 Meggyes M, Lajko A, Fulop BD, Reglodi D, Szereday L. Phenotypic characterization of testicular immune cells expressing immune checkpoint molecules in wild-type and pituitary adenylate cyclase-activating polypeptide-deficient mice. Am J Reprod Immunol 2020;83:e13212. [PMID: 31758623 DOI: 10.1111/aji.13212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
579 Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol 2020;13:105. [PMID: 32723363 DOI: 10.1186/s13045-020-00940-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
580 Dipasquale A, Persico P, Lorenzi E, Rahal D, Santoro A, Simonelli M. COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. J Immunother Cancer 2021;9:e001870. [PMID: 33574054 DOI: 10.1136/jitc-2020-001870] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
581 Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G, Barni S, Berruti A, Brighenti M. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy 2020;43:1-7. [DOI: 10.1097/cji.0000000000000300] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
582 Sarraj B, Ye J, Akl AI, Chen G, Wang JJ, Zhang Z, Abadja F, Abecassis M, Miller SD, Kansas GS, Ansari MJ. Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proc Natl Acad Sci U S A 2014;111:12145-50. [PMID: 25092331 DOI: 10.1073/pnas.1303676111] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
583 Brahm CG, van Linde ME, Enting RH, Schuur M, Otten RHJ, Heymans MW, Verheul HMW, Walenkamp AME. The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. Cancers (Basel) 2020;12:E586. [PMID: 32143288 DOI: 10.3390/cancers12030586] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
584 Brummelman J, Pilipow K, Lugli E. The Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells. Biology of T Cells - Part A. Elsevier; 2018. pp. 63-124. [DOI: 10.1016/bs.ircmb.2018.05.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
585 Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics 2017;9:59. [PMID: 28572863 DOI: 10.1186/s13148-017-0358-y] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 16.4] [Reference Citation Analysis]
586 Post CCB, Westermann AM, Bosse T, Creutzberg CL, Kroep JR. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol 2020;152:102973. [PMID: 32497971 DOI: 10.1016/j.critrevonc.2020.102973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
587 Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233-42. [PMID: 23478000 DOI: 10.1016/j.ejca.2013.02.015] [Cited by in Crossref: 246] [Cited by in F6Publishing: 267] [Article Influence: 27.3] [Reference Citation Analysis]
588 Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol 2019;16:613-30. [PMID: 31501534 DOI: 10.1038/s41585-019-0226-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
589 Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, Lu X. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. J Immunother 2016;39:171-80. [PMID: 27070448 DOI: 10.1097/CJI.0000000000000122] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
590 Bracamonte-Baran W, Čiháková D. Cardiac Autoimmunity: Myocarditis. Adv Exp Med Biol 2017;1003:187-221. [PMID: 28667560 DOI: 10.1007/978-3-319-57613-8_10] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 10.4] [Reference Citation Analysis]
591 Narayanan A, Knollmann FD, Walby JAS, Lim S, Gandara DR, Riess JW. EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. Clin Lung Cancer 2019;20:e238-41. [PMID: 30679078 DOI: 10.1016/j.cllc.2018.12.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
592 Li S, Zhang H, Wei X. Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery. Life (Basel) 2021;11:965. [PMID: 34575114 DOI: 10.3390/life11090965] [Reference Citation Analysis]
593 Leung D, Bonacorsi S, Smith RA, Weber W, Hayes W. Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic. Front Oncol 2021;11:698425. [PMID: 34497758 DOI: 10.3389/fonc.2021.698425] [Reference Citation Analysis]
594 Abdolahi S, Ghazvinian Z, Muhammadnejad S, Ahmadvand M, Aghdaei HA, Ebrahimi-Barough S, Ai J, Zali MR, Verdi J, Baghaei K. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. Front Pharmacol 2021;12:733075. [PMID: 34588986 DOI: 10.3389/fphar.2021.733075] [Reference Citation Analysis]
595 Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012;120:1412-21. [PMID: 22547582 DOI: 10.1182/blood-2012-02-411678] [Cited by in Crossref: 230] [Cited by in F6Publishing: 223] [Article Influence: 23.0] [Reference Citation Analysis]
596 Kim WY, Jung HY, Nam SJ, Kim TM, Heo DS, Kim C, Jeon YK. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch 2016;469:581-90. [DOI: 10.1007/s00428-016-2011-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
597 Avila-Calderón ED, Otero-Olarra JE, Flores-Romo L, Peralta H, Aguilera-Arreola MG, Morales-García MR, Calderón-Amador J, Medina-Chávez O, Donis-Maturano L, Ruiz-Palma MDS, Contreras-Rodríguez A. The Outer Membrane Vesicles of Aeromonas hydrophila ATCC® 7966TM: A Proteomic Analysis and Effect on Host Cells. Front Microbiol 2018;9:2765. [PMID: 30519218 DOI: 10.3389/fmicb.2018.02765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
598 Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010;24:1160-70. [PMID: 20428207 DOI: 10.1038/leu.2010.75] [Cited by in Crossref: 321] [Cited by in F6Publishing: 304] [Article Influence: 26.8] [Reference Citation Analysis]
599 Song B, Aoki S, Liu C, Susukida T, Ito K. An animal model of abacavir-induced HLA-mediated liver injury. Toxicol Sci. 2018;162:713-723. [PMID: 29319822 DOI: 10.1093/toxsci/kfy001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
600 Wei R, Guo L, Wang Q, Miao J, Kwok HF, Lin Y. Targeting PD-L1 Protein: Translation, Modification and Transport. CPPS 2018;20:82-91. [DOI: 10.2174/1389203719666180928105632] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
601 Zerdes I, Wallerius M, Sifakis EG, Wallmann T, Betts S, Bartish M, Tsesmetzis N, Tobin NP, Coucoravas C, Bergh J, Rassidakis GZ, Rolny C, Foukakis T. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers (Basel) 2019;11:E1479. [PMID: 31581535 DOI: 10.3390/cancers11101479] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
602 Saigusa S, Toiyama Y, Tanaka K, Inoue Y, Mori K, Ide S, Imaoka H, Kawamura M, Mohri Y, Kusunoki M. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int J Clin Oncol 2016;21:946-52. [PMID: 26919982 DOI: 10.1007/s10147-016-0962-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
603 Voorwerk L, Kat M, Kok M. Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management 2018;7:BMT05. [DOI: 10.2217/bmt-2017-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
604 Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012;10:859-80. [PMID: 22638109 DOI: 10.1158/1541-7786.MCR-12-0117] [Cited by in Crossref: 100] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
605 Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, Blazar BR, Soiffer RJ, Antin JH, Ritz J. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood 2016;127:2489-97. [PMID: 26944544 DOI: 10.1182/blood-2015-12-688895] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 10.7] [Reference Citation Analysis]
606 Wang S, Chen L. Structural immunology of costimualtory and coinhibitory molecules. Sci China Life Sci 2010;53:183-9. [PMID: 20596825 DOI: 10.1007/s11427-010-0043-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
607 Kang S, Lee S, Park S. iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers (Basel) 2020;12:E1906. [PMID: 32847045 DOI: 10.3390/polym12091906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
608 Wilson KL, Flanagan KL, Prakash MD, Plebanski M. Malaria vaccines in the eradication era: current status and future perspectives. Expert Rev Vaccines 2019;18:133-51. [PMID: 30601095 DOI: 10.1080/14760584.2019.1561289] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
609 Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, Naquet P, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N. IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology 2015;4:e974959. [PMID: 25949872 DOI: 10.4161/2162402X.2014.974959] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
610 Liang ZZ, Guo C, Zou MM, Meng P, Zhang TT. circRNA-miRNA-mRNA regulatory network in human lung cancer: an update. Cancer Cell Int 2020;20:173. [PMID: 32467668 DOI: 10.1186/s12935-020-01245-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
611 Yao Q, Fischer KP, Tyrrell DL, Gutfreund KS. Molecular cloning, expression and characterization of Pekin duck programmed death-1. Gene 2019;702:182-93. [PMID: 30910561 DOI: 10.1016/j.gene.2019.03.035] [Reference Citation Analysis]
612 Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, Freeman GJ, Krogsgaard M, Riley JL. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A 2013;110:E2480-9. [PMID: 23610399 DOI: 10.1073/pnas.1305394110] [Cited by in Crossref: 164] [Cited by in F6Publishing: 168] [Article Influence: 18.2] [Reference Citation Analysis]
613 Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. Cancer Chemother Pharmacol 2020;86:497-505. [PMID: 32936316 DOI: 10.1007/s00280-020-04142-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
614 Magee CN, Boenisch O, Najafian N. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant. 2012;12:2588-2600. [PMID: 22759274 DOI: 10.1111/j.1600-6143.2012.04180.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
615 Huang C, Chiang S, Ke T, Chen T, Lan Y, You Y, Shiau A, Chen WT, Chao KSC. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. Cancer Immunol Immunother 2018;67:551-62. [DOI: 10.1007/s00262-017-2109-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
616 Mulder TA, Wahlin BE, Österborg A, Palma M. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. Cancers (Basel) 2019;11:E915. [PMID: 31261914 DOI: 10.3390/cancers11070915] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
617 Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 2009;183:7898-908. [PMID: 20007574 DOI: 10.4049/jimmunol.0901060] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
618 Holm H, Santi N, Kjøglum S, Perisic N, Skugor S, Evensen Ø. Difference in skin immune responses to infection with salmon louse (Lepeophtheirus salmonis) in Atlantic salmon (Salmo salar L.) of families selected for resistance and susceptibility. Fish Shellfish Immunol 2015;42:384-94. [PMID: 25449368 DOI: 10.1016/j.fsi.2014.10.038] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
619 Kovaleva OV, Rashidova MA, Gratchev AN, Maslennikov VV, Boulitcheva IV, Gershtein ES, Korotkova EA, Sokolov NY, Delektorskaya VV, Mamedli ZZ, Kushlinskii NE. Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer. Dokl Biochem Biophys 2021;497:66-70. [PMID: 33895919 DOI: 10.1134/S1607672921020095] [Reference Citation Analysis]
620 Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 2017;130:2265-70. [PMID: 29167175 DOI: 10.1182/blood-2017-06-781989] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
621 Yan Z, Zhuansun Y, Chen R, Li J, Ran P. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Exp Cell Res. 2014;324:65-74. [PMID: 24681107 DOI: 10.1016/j.yexcr.2014.03.013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 6.5] [Reference Citation Analysis]
622 Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Gao YT, Jiang Y, Gao YQ. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. Lab Invest 2016;96:1156-64. [PMID: 27617403 DOI: 10.1038/labinvest.2016.96] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
623 Shibru B, Fey K, Fricke S, Blaudszun AR, Fürst F, Weise M, Seiffert S, Weyh MK, Köhl U, Sack U, Boldt A. Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry. Front Immunol 2021;12:694055. [PMID: 34276685 DOI: 10.3389/fimmu.2021.694055] [Reference Citation Analysis]
624 Cheng LS, Liu Y, Jiang W. Restoring homeostasis of CD4+ T cells in hepatitis-B-virus-related liver fibrosis. World J Gastroenterol 2015; 21(38): 10721-10731 [PMID: 26478664 DOI: 10.3748/wjg.v21.i38.10721] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
625 Waldmann H. Immunological Tolerance. Reference Module in Biomedical Sciences. Elsevier; 2014. [DOI: 10.1016/b978-0-12-801238-3.00116-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
626 Kong M, Zhou D. Establishment of universal human embryonic stem cell lines. Immunol Lett 2021;230:59-62. [PMID: 33309828 DOI: 10.1016/j.imlet.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
627 Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther 2020;27:841-53. [PMID: 32341410 DOI: 10.1038/s41417-020-0174-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
628 Owada T, Watanabe N, Oki M, Oya Y, Saito Y, Saito T, Iwamoto I, Murphy TL, Murphy KM, Nakajima H. Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells. J Leukoc Biol 2010;87:425-32. [PMID: 19892849 DOI: 10.1189/jlb.0309138] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
629 Carman CV, Martinelli R. T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity. Front Immunol 2015;6:603. [PMID: 26635815 DOI: 10.3389/fimmu.2015.00603] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
630 Huang H, Ma Y, Dawicki W, Zhang X, Gordon JR. Comparison of induced versus natural regulatory T cells of the same TCR specificity for induction of tolerance to an environmental antigen. J Immunol 2013;191:1136-43. [PMID: 23817420 DOI: 10.4049/jimmunol.1201899] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
631 Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M, Dong H, Forman S, Martin PJ, Chen YZ, Wang J, Zeng D. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest 2017;127:1960-77. [PMID: 28414296 DOI: 10.1172/JCI91138] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 11.2] [Reference Citation Analysis]
632 Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood 2017;129:275-9. [DOI: 10.1182/blood-2016-08-731885] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 10.6] [Reference Citation Analysis]
633 Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Front Immunol 2017;8:1482. [PMID: 29163543 DOI: 10.3389/fimmu.2017.01482] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
634 Costa F, Das R, Kini Bailur J, Dhodapkar K, Dhodapkar MV. Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Front Immunol 2018;9:2204. [PMID: 30319648 DOI: 10.3389/fimmu.2018.02204] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
635 Kaufmann SH. Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med 2010;267:337-53. [PMID: 20433580 DOI: 10.1111/j.1365-2796.2010.02216.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
636 Hude I, Sasse S, Engert A, Bröckelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017;102:30-42. [PMID: 27884973 DOI: 10.3324/haematol.2016.150656] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
637 Nagai K. Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. Front Med (Lausanne) 2020;7:584382. [PMID: 33251233 DOI: 10.3389/fmed.2020.584382] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
638 Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020;85:106628. [DOI: 10.1016/j.intimp.2020.106628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
639 Leitner J, Kuschei W, Grabmeier-Pfistershammer K, Woitek R, Kriehuber E, Majdic O, Zlabinger G, Pickl WF, Steinberger P. T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J Immunol Methods 2010;362:131-41. [PMID: 20858499 DOI: 10.1016/j.jim.2010.09.020] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
640 Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 2011;187:1537-41. [PMID: 21768399 DOI: 10.4049/jimmunol.1100660] [Cited by in Crossref: 129] [Cited by in F6Publishing: 120] [Article Influence: 11.7] [Reference Citation Analysis]
641 Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, O'Sullivan KE, Doherty DG, Geoghegan JG, Ravi N, O'Farrelly C, Reynolds JV, Lysaght J. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma. Cancer Lett 2018;418:230-8. [PMID: 29339209 DOI: 10.1016/j.canlet.2018.01.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
642 Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, Ma Y, Yang Y, Huang Y, Zhao H, Xu R, Hong S, Zhang L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019;7:322. [PMID: 31753012 DOI: 10.1186/s40425-019-0808-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 13.7] [Reference Citation Analysis]
643 Mariappan V, Vellasamy KM, Barathan M, Girija ASS, Shankar EM, Vadivelu J. Hijacking of the Host's Immune Surveillance Radars by Burkholderia pseudomallei. Front Immunol 2021;12:718719. [PMID: 34456925 DOI: 10.3389/fimmu.2021.718719] [Reference Citation Analysis]
644 Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y, Li K. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 2020;11:309. [PMID: 32366856 DOI: 10.1038/s41419-020-2511-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
645 Hid Cadena R, Abdulahad WH, Hospers GAP, Wind TT, Boots AMH, Heeringa P, Brouwer E. Checks and Balances in Autoimmune Vasculitis. Front Immunol 2018;9:315. [PMID: 29520282 DOI: 10.3389/fimmu.2018.00315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
646 Leal AS, Zydeck K, Carapellucci S, Reich LA, Zhang D, Moerland JA, Sporn MB, Liby KT. Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. NPJ Breast Cancer 2019;5:39. [PMID: 31700995 DOI: 10.1038/s41523-019-0135-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
647 Sahler JM, Eade CR, Altier C, March JC. Salmonella enterica Serovar Typhimurium Increases Functional PD-L1 Synergistically with Gamma Interferon in Intestinal Epithelial Cells via Salmonella Pathogenicity Island 2. Infect Immun 2018;86:e00674-17. [PMID: 29440366 DOI: 10.1128/IAI.00674-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
648 Hayakawa N, Kikuchi E, Mikami S, Fukumoto K, Oya M. The Role of PD-1 Positivity in the Tumour Nest on Clinical Outcome in Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy. Clin Oncol (R Coll Radiol) 2018;30:e1-8. [PMID: 29153625 DOI: 10.1016/j.clon.2017.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
649 Kaufmann SH, Hussey G, Lambert P. New vaccines for tuberculosis. The Lancet 2010;375:2110-9. [DOI: 10.1016/s0140-6736(10)60393-5] [Cited by in Crossref: 184] [Cited by in F6Publishing: 84] [Article Influence: 15.3] [Reference Citation Analysis]
650 Tong M, Wang J, He W, Wang Y, Pan H, Li D, Zhang H. Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res 2018;10:4501-7. [PMID: 30349382 DOI: 10.2147/CMAR.S179680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
651 de Jong FC, Rutten VC, Zuiverloon TCM, Theodorescu D. Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer. Int J Mol Sci 2021;22:2800. [PMID: 33802033 DOI: 10.3390/ijms22062800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
652 Li R, Lee J, Kim MS, Liu V, Moulik M, Li H, Yi Q, Xie A, Chen W, Yang L, Li Y, Tsai TH, Oka K, Chan L, Yechoor V. PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice. Diabetes 2015;64:529-40. [PMID: 25332429 DOI: 10.2337/db13-1737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
653 Morciano G, Vezzani B, Missiroli S, Boncompagni C, Pinton P, Giorgi C. An Updated Understanding of the Role of YAP in Driving Oncogenic Responses. Cancers (Basel) 2021;13:3100. [PMID: 34205830 DOI: 10.3390/cancers13123100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
654 Bhadra R, Cobb DA, Weiss LM, Khan IA. Psychiatric disorders in toxoplasma seropositive patients--the CD8 connection. Schizophr Bull 2013;39:485-9. [PMID: 23427221 DOI: 10.1093/schbul/sbt006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
655 Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int J Mol Sci 2018;19:E3595. [PMID: 30441809 DOI: 10.3390/ijms19113595] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
656 Lee MY, Park CJ, Cho YU, You E, Jang S, Seol CA, Seo EJ, Choi EJ, Lee JH. Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication. Cancer Immunol Immunother 2020;69:2223-32. [PMID: 32474769 DOI: 10.1007/s00262-020-02617-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
657 Chen T, Li Q, Liu Z, Chen Y, Feng F, Sun H. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy? Eur J Med Chem 2019;161:378-98. [PMID: 30384043 DOI: 10.1016/j.ejmech.2018.10.044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
658 Yao Q, Fischer KP, Tyrrell DL, Gutfreund KS. The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis. Int J Immunogenet 2015;42:111-20. [PMID: 25556810 DOI: 10.1111/iji.12175] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
659 Abou Zahr A, Bernabe Ramirez C, Wozney J, Prebet T, Zeidan AM. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Expert Review of Hematology 2016;9:377-88. [DOI: 10.1586/17474086.2016.1135047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
660 Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011;42:552-7. [PMID: 21237493 DOI: 10.1016/j.humpath.2010.08.015] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
661 Fonsatti E, Maio M, Altomonte M, Hersey P. Biology and Clinical Applications of CD40 in Cancer Treatment. Seminars in Oncology 2010;37:517-23. [DOI: 10.1053/j.seminoncol.2010.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
662 Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J, Lim M. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res 2016;2016:4683607. [PMID: 26881264 DOI: 10.1155/2016/4683607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
663 Zhang SA, Niyazi HE, Hong W, Tuluwengjiang GL, Zhang L, Zhang Y, Su WP, Bao YX. Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. Tumour Biol 2017;39:1010428317692237. [PMID: 28351328 DOI: 10.1177/1010428317692237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
664 Mariotti FR, Quatrini L, Munari E, Vacca P, Tumino N, Pietra G, Mingari MC, Moretta L. Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. Br J Pharmacol 2020;177:2889-903. [PMID: 32335915 DOI: 10.1111/bph.15081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
665 Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. [PMID: 28018338 DOI: 10.3389/fimmu.2016.00550] [Cited by in Crossref: 219] [Cited by in F6Publishing: 226] [Article Influence: 36.5] [Reference Citation Analysis]
666 Mir MA. T-Cell Costimulation and Its Applications in Diseases. Developing Costimulatory Molecules for Immunotherapy of Diseases. Elsevier; 2015. pp. 255-92. [DOI: 10.1016/b978-0-12-802585-7.00006-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
667 Giraldo NA, Becht E, Vano Y, Sautès-fridman C, Fridman WH. The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch 2015;467:127-35. [DOI: 10.1007/s00428-015-1787-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
668 Magryś A, Paluch-Oleś J, Bogut A, Kiełbus M, Plewik D, Kozioł-Montewka M. The role of programmed death ligand 1 pathway in persistent biomaterial-associated infections. J Microbiol 2015;53:544-52. [PMID: 26224457 DOI: 10.1007/s12275-015-5022-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
669 Abbas M, Steffens S, Bellut M, Eggers H, Großhennig A, Becker JU, Wegener G, Schrader AJ, Grünwald V, Ivanyi P. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med Oncol 2016;33:80. [PMID: 27317388 DOI: 10.1007/s12032-016-0794-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
670 Amancha PK, Hong JJ, Rogers K, Ansari AA, Villinger F. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. J Immunol 2013;191:6060-70. [PMID: 24227774 DOI: 10.4049/jimmunol.1302044] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
671 Alambeladi S, Hosseiny S, Jafarinia M, Dianatpour M. Use of dual-transfection for programmed death cell protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells. Iran J Basic Med Sci 2021;24:44-50. [PMID: 33643569 DOI: 10.22038/ijbms.2020.48566.11146] [Reference Citation Analysis]
672 Batman S, Matsuo K, Mhawech-Fauceglia P, Munro E, Weisenberger M, Allen A, Joshi S, Machida H, Matsuzaki S, Bozanovic T, Pejovic T. Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer. Cancers (Basel) 2021;13:1972. [PMID: 33923934 DOI: 10.3390/cancers13081972] [Reference Citation Analysis]
673 Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012;2012:670957. [PMID: 22474480 DOI: 10.1155/2012/670957] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
674 Schoenhals JE, Seyedin SN, Anderson C, Brooks ED, Li YR, Younes AI, Niknam S, Li A, Barsoumian HB, Cortez MA, Welsh JW. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res 2017;6:148-58. [PMID: 28529897 DOI: 10.21037/tlcr.2017.03.06] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
675 Dotti G. Blocking PD-1 in cancer immunotherapy. Blood 2009;114:1457-8. [DOI: 10.1182/blood-2009-05-223412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
676 Ren J, Wang A, Liu J, Yuan Q. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma. Bioengineered 2021;12:4331-48. [PMID: 34338158 DOI: 10.1080/21655979.2021.1951522] [Reference Citation Analysis]
677 Zacca ER, Onofrio LI, Acosta CDV, Ferrero PV, Alonso SM, Ramello MC, Mussano E, Onetti L, Cadile II, Stancich MI, Taboada Bonfanti MC, Montes CL, Acosta Rodríguez EV, Gruppi A. PD-L1+ Regulatory B Cells Are Significantly Decreased in Rheumatoid Arthritis Patients and Increase After Successful Treatment. Front Immunol 2018;9:2241. [PMID: 30327652 DOI: 10.3389/fimmu.2018.02241] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
678 Arranz-Nicolás J, Martin-Salgado M, Rodríguez-Rodríguez C, Liébana R, Moreno-Ortiz MC, Leitner J, Steinberger P, Ávila-Flores A, Merida I. Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes. J Immunother Cancer 2020;8:e001521. [PMID: 33246984 DOI: 10.1136/jitc-2020-001521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
679 Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol 2018;52:379-88. [PMID: 29345283 DOI: 10.3892/ijo.2017.4221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
680 Lewinsky H, Barak AF, Huber V, Kramer MP, Radomir L, Sever L, Orr I, Mirkin V, Dezorella N, Shapiro M, Cohen Y, Shvidel L, Seiffert M, Herishanu Y, Becker-Herman S, Shachar I. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia. J Clin Invest 2018;128:5465-78. [PMID: 30277471 DOI: 10.1172/JCI96610] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
681 Merida I, Andrada E, Gharbi SI, Avila-flores A. Redundant and specialized roles for diacylglycerol kinases   and   in the control of T cell functions. Science Signaling 2015;8:re6-re6. [DOI: 10.1126/scisignal.aaa0974] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
682 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68. [PMID: 32433532 DOI: 10.1038/s41577-020-0306-5] [Cited by in Crossref: 280] [Cited by in F6Publishing: 291] [Article Influence: 140.0] [Reference Citation Analysis]
683 Swamynathan S, Loughner CL, Swamynathan SK. Inhibition of HUVEC tube formation via suppression of NFκB suggests an anti-angiogenic role for SLURP1 in the transparent cornea. Exp Eye Res 2017;164:118-28. [PMID: 28803936 DOI: 10.1016/j.exer.2017.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
684 Cai Y, Wang F, Liu Q, Li Z, Li D, Sun Z. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. Invest New Drugs 2019;37:799-809. [PMID: 30368626 DOI: 10.1007/s10637-018-0678-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
685 Mletzko S, Pinato DJ, Robey RC, Dalla Pria A, Benson P, Imami N, Bower M. Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. Oncoimmunology 2017;6:e1304337. [PMID: 28919987 DOI: 10.1080/2162402X.2017.1304337] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
686 Sui X, Ma J, Han W, Wang X, Fang Y, Li D, Pan H, Zhang L. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget 2015;6:19393-404. [PMID: 26305724 DOI: 10.18632/oncotarget.5107] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
687 Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Koreth J. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv 2019;3:2550-61. [PMID: 31471324 DOI: 10.1182/bloodadvances.2019000631] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
688 Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM, Kaanders JH. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121:3100-3108. [PMID: 21765211 DOI: 10.1172/jci43656] [Cited by in Crossref: 177] [Cited by in F6Publishing: 105] [Article Influence: 16.1] [Reference Citation Analysis]
689 Shindo Y, Unsinger J, Burnham CA, Green JM, Hotchkiss RS. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock 2015;43:334-43. [PMID: 25565644 DOI: 10.1097/SHK.0000000000000317] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
690 Lu X, Liu J, Li H, Li W, Wang X, Ma J, Tong Q, Wu K, Wang G. Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-β1. J Surg Oncol. 2011;104:571-577. [PMID: 21695703 DOI: 10.1002/jso.22005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
691 Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. Future Oncol 2019;15:533-41. [PMID: 30624089 DOI: 10.2217/fon-2018-0571] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
692 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264. [PMID: 22437870 DOI: 10.1038/nrc3239] [Cited by in Crossref: 6827] [Cited by in F6Publishing: 6453] [Article